0
Mappings
2
Definitions
0
Inheritance
13
Pathophysiology
0
Histopathology
12
Phenotypes
20
Pathograph
0
Genes
4
Treatments
3
Subtypes
3
Differentials
3
Datasets
2
Trials
0
Models
1
Literature
🏷

Classifications

Harrison's Chapter
infectious disease parasitic infectious disease
📘

Definitions

2
Clinical case framing for giardiasis
Giardiasis is a protozoal gastrointestinal infection with clinical spectra ranging from asymptomatic carriage to acute or chronic diarrheal disease.
CASE_DEFINITION Clinical framing for symptomatic and asymptomatic Giardia infection
Show evidence (2 references)
PMID:30020611 SUPPORT Other
"The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating; however, asymptomatic colonization is also common."
Supports a broad clinical case definition that includes both symptomatic disease and asymptomatic carriage.
PMID:37764167 SUPPORT Other
"The severity of the symptoms and clinical manifestations in children may vary from asymptomatic to life-threatening depending on the Cryptosporidium species/G. duodenalis strains and the resulting complex stepwise interactions between the parasite, the host nutritional and immunologic status,..."
Adds independent pediatric-focused support for broad clinical severity spectrum from asymptomatic to severe disease.
Stool-based diagnostic confirmation framework
Diagnosis can be supported by stool antigen immunoassay and repeated stool microscopy when early samples are negative after exposure.
DIAGNOSTIC_CRITERIA Routine diagnosis of suspected giardiasis after relevant exposure
Show evidence (2 references)
PMID:2674196 SUPPORT Human Clinical
"Its sensitivity and specificity were 96 and 100%, respectively, while the sensitivity and specificity of O&P examination were 74 and 100%, respectively."
Supports high diagnostic performance of stool antigen immunoassay relative to microscopy.
PMID:68190 SUPPORT Human Clinical
"A practical conclusion was that, in suspected cases of giardiasis with negative stool findings during the first 3 wk after possible exposure to Giardia, examination of repeated faecal samples is still effective in confirming the diagnosis."
Supports repeated stool testing when initial early examinations are negative.

Subtypes

3
clinical course
Acute symptomatic giardiasis
Predominantly acute diarrheal illness after Giardia exposure.
Show evidence (1 reference)
PMID:30020611 SUPPORT Other
"The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating; however, asymptomatic colonization is also common."
Supports an acute symptomatic phenotype subtype.
Chronic giardiasis with malabsorption
Persistent infection phenotype associated with malabsorption and weight loss.
Show evidence (2 references)
PMID:30020611 SUPPORT Other
"In some patients, a chronic infection may lead to malabsorption and weight loss."
Supports a chronic malabsorptive subtype.
PMID:35250996 SUPPORT Other
"Chronic G. duodenalis infections cause a malabsorption syndrome that may lead to failure to thrive and/or stunted growth, especially in children in developing countries."
Provides independent support that chronic infection can progress to clinically significant malabsorptive and growth-impacting disease.
treatment response
Refractory or treatment-resistant giardiasis
Cases with persistent infection despite standard nitroimidazole therapy.
Show evidence (1 reference)
DOI:10.1128/aac.00731-23 SUPPORT Other
"Fexinidazole and its metabolites were also active against a metronidazole-resistant strain of G. lamblia."
Supports existence of metronidazole-resistant/refractory disease context.
📚

References

10
Current Understanding of Giardia lamblia and Pathogenesis of Stunting and Cognitive Deficits in Children from Low- and Middle-Income Countries
1 finding
Current Understanding of Giardia lamblia and Pathogenesis of Stunting and Cognitive Deficits in Children from Low- and Middle-Income Countries
"Current Understanding of Giardia lamblia and Pathogenesis of Stunting and Cognitive Deficits in Children from Low- and Middle-Income Countries"
Occurrence and assemblage distribution of Giardia Duodenalis in symptomatic and asymptomatic patients in southeastern Iran (2019–2022)
1 finding
Occurrence and assemblage distribution of Giardia Duodenalis in symptomatic and asymptomatic patients in southeastern Iran (2019–2022)
"Occurrence and assemblage distribution of Giardia Duodenalis in symptomatic and asymptomatic patients in southeastern Iran (2019–2022)"
Giardia lamblia risk factors and burden in children with acute gastroenteritis in a Nicaraguan birth cohort
1 finding
Giardia lamblia is an intestinal protozoan estimated to cause ~200 million symptomatic infections annually, mainly in children in low- and middle-income countries associated with intestinal damage, increased permeability, and malabsorption.
"Giardia lamblia is an intestinal protozoan estimated to cause ~200 million symptomatic infections annually, mainly in children in low- and middle-income countries associated with intestinal damage, increased permeability, and malabsorption."
Show evidence (1 reference)
DOI:10.1371/journal.pntd.0012230 SUPPORT Human Clinical
"Giardia lamblia is an intestinal protozoan estimated to cause ~200 million symptomatic infections annually, mainly in children in low- and middle-income countries associated with intestinal damage, increased permeability, and malabsorption."
Deep research cited this publication as relevant literature for Giardiasis.
Protozoan Infections Acquired from Food or Drinking Water: An Update
1 finding
Protozoan Infections Acquired from Food or Drinking Water: An Update
"This review summarizes the most recent developments of research on protozoan parasite infections ac-quired through food and drinking water and is aimed at gathering updated knowledge on the risk factors, illnesses caused, and measures for prevention."
Show evidence (1 reference)
"This review summarizes the most recent developments of research on protozoan parasite infections ac-quired through food and drinking water and is aimed at gathering updated knowledge on the risk factors, illnesses caused, and measures for prevention."
Deep research cited this publication as relevant literature for Giardiasis.
Waterborne <i>Cryptosporidium</i> species and <i>Giardia duodenalis</i> in resources of MENA: A systematic review and meta-analysis
1 finding
This review explores our understanding of Cryptosporidium species and Giardia duodenalis distribution in Middle East and North African (MENA) water resources.
"This review explores our understanding of Cryptosporidium species and Giardia duodenalis distribution in Middle East and North African (MENA) water resources."
Show evidence (1 reference)
DOI:10.2166/wh.2024.107 SUPPORT Other
"This review explores our understanding of Cryptosporidium species and Giardia duodenalis distribution in Middle East and North African (MENA) water resources."
Deep research cited this publication as relevant literature for Giardiasis.
Autochthonous and imported giardiasis cases: An analysis of two decades of national surveillance data, Germany, 2002 to 2021
1 finding
Giardia duodenalis is a major cause of gastroenteritis globally, and is the most common food- and waterborne parasitic infection in Europe.
"Giardia duodenalis is a major cause of gastroenteritis globally, and is the most common food- and waterborne parasitic infection in Europe."
Show evidence (1 reference)
"Giardia duodenalis is a major cause of gastroenteritis globally, and is the most common food- and waterborne parasitic infection in Europe."
Deep research cited this publication as relevant literature for Giardiasis.
Systematic Review of Diagnostic Approaches for Human Giardiasis: Unveiling Optimal Strategies
1 finding
Giardiasis, caused by the protozoan Giardia intestinalis, affects around 400 million people worldwide, emphasizing the critical need for accurate diagnosis to enhance human health, especially in children.
"Giardiasis, caused by the protozoan Giardia intestinalis, affects around 400 million people worldwide, emphasizing the critical need for accurate diagnosis to enhance human health, especially in children."
Show evidence (1 reference)
"Giardiasis, caused by the protozoan Giardia intestinalis, affects around 400 million people worldwide, emphasizing the critical need for accurate diagnosis to enhance human health, especially in children."
Deep research cited this publication as relevant literature for Giardiasis.
The Influence of the Protozoan Giardia lamblia on the Modulation of the Immune System and Alterations in Host Glucose and Lipid Metabolism
1 finding
Giardia lamblia, the cause of giardiasis, significantly impacts patients with metabolic disorders related to insulin resistance (IR).
"Giardia lamblia, the cause of giardiasis, significantly impacts patients with metabolic disorders related to insulin resistance (IR)."
Show evidence (1 reference)
DOI:10.3390/ijms25168627 SUPPORT Human Clinical
"Giardia lamblia, the cause of giardiasis, significantly impacts patients with metabolic disorders related to insulin resistance (IR)."
Deep research cited this publication as relevant literature for Giardiasis.
GIARDÍASE: DIAGNÓSTICO, TRATAMENTO E ABORDAGENS MULTIDISCIPLINARES
1 finding
A giardíase é uma infecção intestinal causada pelo protozoário Giardia lamblia, frequentemente associada a quadros de diarreia, dor abdominal e desidratação.
"A giardíase é uma infecção intestinal causada pelo protozoário Giardia lamblia, frequentemente associada a quadros de diarreia, dor abdominal e desidratação."
Show evidence (1 reference)
"A giardíase é uma infecção intestinal causada pelo protozoário Giardia lamblia, frequentemente associada a quadros de diarreia, dor abdominal e desidratação."
Deep research cited this publication as relevant literature for Giardiasis.
Perspectives on the Drug Discovery of Intestinal Protozoan Parasites
1 finding
The intestinal protozoan parasites pose serious health concerns, infecting more than one billion individuals every year and mainly causing diarrhea in infants and adults.
"The intestinal protozoan parasites pose serious health concerns, infecting more than one billion individuals every year and mainly causing diarrhea in infants and adults."
Show evidence (1 reference)
DOI:10.5772/intechopen.1005559 SUPPORT Human Clinical
"The intestinal protozoan parasites pose serious health concerns, infecting more than one billion individuals every year and mainly causing diarrhea in infants and adults."
Deep research cited this publication as relevant literature for Giardiasis.

Pathophysiology

13
Ingestion of infectious Giardia cysts
Infection begins with ingestion of environmentally transmitted cysts.
Show evidence (1 reference)
PMID:30020611 SUPPORT Other
"Giardiasis, caused by the protozoan parasite Giardia duodenalis, is one of the most common treatable causes of gastroenteritis worldwide, with a burden higher in low-income countries."
Supports Giardia exposure as the initiating infectious event.
Trophozoite colonization of the proximal small-intestinal epithelial surface
Giardia trophozoites persist at the proximal small-intestinal lumen-epithelium interface without mucosal invasion.
small intestine link
Show evidence (1 reference)
DOI:10.1128/iai.00065-24 SUPPORT Model Organism
"G. lamblia resides in the lumen and at the epithelial surface of the proximal small intestine but is not mucosa invasive."
Supports non-invasive luminal colonization as a discrete mechanistic stage.
Assemblage-specific trophozoite-epithelial injury signaling
Host epithelial injury severity varies by Giardia assemblage and can intensify during mixed infections.
Show evidence (1 reference)
PMID:22924932 SUPPORT In Vitro
"Furthermore, infections by isolates in combination with isolates from another assemblage enhanced the epithelial disruption and apoptosis."
Supports increased epithelial injury in mixed-assemblage infection contexts.
Caspase-3-dependent enterocyte apoptosis
Giardia-induced epithelial injury triggers caspase-3-dependent enterocyte apoptosis.
enterocyte link
apoptotic process link
Show evidence (1 reference)
PMID:22924932 SUPPORT In Vitro
"All disruptions were caspase-3 dependent and were more pronounced when caused by a non-host specific assemblage."
Supports caspase-3 dependence of trophozoite-induced epithelial apoptosis.
Tight-junction disassembly in infected enterocytes
Giardia infection causes tight-junction disruption in intestinal epithelial cells.
tight junction disassembly link
Show evidence (1 reference)
PMID:22924932 SUPPORT In Vitro
"The results indicate that infection with trophozoites disrupts epithelial tight junctions and induces varying degrees of enterocyte apoptosis, depending on the infecting assemblage."
Supports trophozoite-induced tight-junction disruption as a specific injury event.
Claudin-1 downregulation
Expression of the tight-junction protein claudin-1 is reduced in chronic human giardiasis.
Show evidence (1 reference)
PMID:16935925 SUPPORT Human Clinical
"As structural correlate, reduced claudin 1 expression and increased epithelial apoptosis were detected."
Supports reduced claudin-1 expression in human duodenal giardiasis.
Hypoxia-dependent PKC alpha/beta II dephosphorylation
Low-oxygen conditions in infected IECs drive PKC alpha/beta II dephosphorylation linked to barrier injury.
response to hypoxia link
Show evidence (1 reference)
PMID:35868574 SUPPORT In Vitro
"Collectively, these results support the emerging theory that molecular oxygen impacts gut homeostasis during Giardia infection via direct host signaling pathways."
Supports oxygen-regulated host-signaling perturbation in infected epithelial cells.
Epithelial barrier resistance decline
Human duodenal giardiasis is associated with reduced epithelial resistance and barrier dysfunction.
Show evidence (1 reference)
PMID:16935925 SUPPORT Human Clinical
"Instead, epithelial resistance of giardiasis biopsy specimens was decreased (19 (2) vs 25 (2) Omega cm(2); p<0.05)"
Supports reduced epithelial resistance as a discrete pathophysiologic event.
Sodium-glucose symport impairment
Sodium-dependent glucose transport is reduced in chronic human giardiasis.
Show evidence (1 reference)
PMID:16935925 SUPPORT Human Clinical
"Finally, phlorizin-sensitive Na(+)-glucose symport was reduced in patients with giardiasis (121 (9) vs 83 (14) microA/h/cm(2))."
Supports reduced sodium-glucose symport in chronic human infection.
Electrogenic anion secretion activation
Bumetanide-sensitive secretory current is increased in chronic human giardiasis.
Show evidence (1 reference)
PMID:16935925 SUPPORT Human Clinical
"The bumetanide-sensitive portion of I(SC) in giardiasis was also increased (51 (5) vs 20 (9) microA/h/cm(2) in control; p<0.05)."
Supports activation of a bumetanide-sensitive anion-secretory component.
Mucus layer disruption
Giardia impairs mucus barrier integrity at the host-microbe interface.
Show evidence (1 reference)
PMID:28452685 SUPPORT Other
"We will summarize what is known and discuss preliminary observations suggesting how such enteropathogen directly and/ or indirectly impairs commensal microbiota biofilm architecture, disrupts mucus layer and damages host epithelium physiology and survival."
Supports mucus disruption as a distinct barrier-level event.
Commensal microbiota biofilm impairment
Giardia-associated barrier perturbation disrupts commensal microbiota organization.
Show evidence (1 reference)
PMID:28452685 SUPPORT Other
"We will summarize what is known and discuss preliminary observations suggesting how such enteropathogen directly and/ or indirectly impairs commensal microbiota biofilm architecture, disrupts mucus layer and damages host epithelium physiology and survival."
Supports commensal biofilm impairment as a discrete event in barrier ecosystem pathology.
Malabsorption
Chronic intestinal dysfunction in giardiasis can impair nutrient absorption.
Show evidence (2 references)
PMID:30020611 SUPPORT Other
"In some patients, a chronic infection may lead to malabsorption and weight loss."
Supports malabsorption as a key downstream pathophysiologic outcome.
PMID:35250996 SUPPORT Other
"Chronic G. duodenalis infections cause a malabsorption syndrome that may lead to failure to thrive and/or stunted growth, especially in children in developing countries."
Adds independent support linking chronic giardiasis to malabsorption syndrome and pediatric growth consequences.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Giardiasis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

12
Digestive 5
Diarrhea VERY_FREQUENT Diarrhea (HP:0002014)
Show evidence (1 reference)
PMID:30020611 SUPPORT Other
"The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating; however, asymptomatic colonization is also common."
Supports diarrhea as a hallmark frequent phenotype.
Flatulence FREQUENT Flatulence (HP:0033589)
Show evidence (1 reference)
PMID:30020611 SUPPORT Other
"The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating; however, asymptomatic colonization is also common."
Supports flatulence as a common symptom.
Abdominal distention FREQUENT Abdominal distention (HP:0003270)
Show evidence (1 reference)
PMID:30020611 SUPPORT Other
"The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating; however, asymptomatic colonization is also common."
Supports abdominal bloating/distention as part of the common symptomatic presentation.
Steatorrhea OCCASIONAL Steatorrhea (HP:0002570)
Show evidence (1 reference)
PMID:6750750 SUPPORT Other
"Giardiasis can produce steatorrhea, maldigestion, and malabsorption of carbohydrates and of vitamins A and B12."
Supports steatorrhea as a recognized malabsorptive manifestation.
Malabsorption OCCASIONAL Malabsorption (HP:0002024)
Show evidence (2 references)
PMID:30020611 SUPPORT Other
"In some patients, a chronic infection may lead to malabsorption and weight loss."
Supports malabsorption as an important chronic manifestation.
PMID:35250996 SUPPORT Other
"Chronic G. duodenalis infections cause a malabsorption syndrome that may lead to failure to thrive and/or stunted growth, especially in children in developing countries."
Provides independent support for chronic malabsorption as a clinically important manifestation.
Nervous System 1
Cognitive impairment OCCASIONAL Cognitive impairment (HP:0100543)
Show evidence (2 references)
PMID:14501998 SUPPORT Other
"Further studies of giardiasis in poorly nourished children in developing regions supports an important contributing role of Giardia in stunting and cognitive impairment."
Supports potential neurodevelopmental sequelae (cognitive impairment) in pediatric chronic exposure contexts.
PMID:37764167 SUPPORT Other
"Structural damages inflicted by both parasites to epithelial cells in the large and small intestines could severely impair children's gut health, including the ability to absorb nutrients, resulting in stunted growth, diminished neurocognitive development, and other long-term effects."
Adds independent contemporary support for long-term neurocognitive impact in pediatric disease contexts.
Constitutional 2
Abdominal pain FREQUENT Abdominal pain (HP:0002027)
Show evidence (2 references)
PMID:30020611 SUPPORT Other
"The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating; however, asymptomatic colonization is also common."
Supports abdominal pain as a common clinical manifestation.
PMID:17070814 SUPPORT Other
"Clinical manifestations of Giardia intestinalis infection also vary from asymptomatic carriage to acute and chronic diarrhoea with abdominal pain."
Independent review support for abdominal pain across acute and chronic courses.
Post-infectious dyspepsia OCCASIONAL Dyspepsia (HP:0410281)
Show evidence (1 reference)
"Overall prevalence of PI-IBS and PI-FD were 14.5% and 12.7%, respectively."
Supports post-infectious dyspeptic symptoms (PI-FD) as a recognized long-tail sequela after enteric infection.
Growth 3
Weight loss OCCASIONAL Weight loss (HP:0001824)
Show evidence (1 reference)
PMID:30020611 SUPPORT Other
"In some patients, a chronic infection may lead to malabsorption and weight loss."
Supports weight loss in persistent/chronic disease.
Failure to thrive OCCASIONAL Failure to thrive (HP:0001508)
Show evidence (2 references)
PMID:6750750 SUPPORT Other
"Severe clinical giardiasis can cause "failure to thrive" in young children, but the impact, if any, of subclinical giardiasis on growth in general populations is not well defined."
Supports failure to thrive as a severe pediatric nutritional consequence.
PMID:35250996 SUPPORT Other
"Chronic G. duodenalis infections cause a malabsorption syndrome that may lead to failure to thrive and/or stunted growth, especially in children in developing countries."
Adds newer independent support for failure-to-thrive risk in chronic pediatric infection.
Growth delay OCCASIONAL Growth delay (HP:0001510)
Show evidence (2 references)
PMID:14501998 SUPPORT Other
"Further studies of giardiasis in poorly nourished children in developing regions supports an important contributing role of Giardia in stunting and cognitive impairment."
Supports growth delay/stunting as a documented pediatric consequence in vulnerable settings.
PMID:37764167 SUPPORT Other
"Structural damages inflicted by both parasites to epithelial cells in the large and small intestines could severely impair children's gut health, including the ability to absorb nutrients, resulting in stunted growth, diminished neurocognitive development, and other long-term effects."
Adds contemporary review support linking intestinal injury and malabsorption to pediatric stunting.
Other 1
Post-infectious irritable bowel syndrome OCCASIONAL irritable bowel syndrome (MONDO:0005052)
Show evidence (2 references)
"PI-IBS was most associated with parasites (prevalence 30.1%), but in only two studies, followed by bacteria (18.3%) and viruses (10.7%)."
Supports parasite-linked post-infectious IBS as a relevant sequela category.
"IBS persisted in 39.8% of subjects in the long-term (>5 years follow-up) after diagnosis."
Supports long-term persistence of this sequela once established.
💊

Treatments

4
Nitroimidazole pharmacotherapy (tinidazole or metronidazole)
Action: pharmacotherapy MAXO:0000058
Agent: tinidazole metronidazole
Nitroimidazoles are core first-line agents for most uncomplicated giardiasis.
Show evidence (2 references)
PMID:15625030 SUPPORT Other
"Tinidazole is the first-line drug treatment of giardiasis, as it requires only a single dose to cure infection in most individuals."
Supports tinidazole as first-line therapy.
PMID:15625030 SUPPORT Other
"The related drug metronidazole is as effective, but it requires 5 to 7 days of three times a day therapy."
Supports metronidazole as an effective alternative regimen.
Nitazoxanide alternative therapy
Action: pharmacotherapy MAXO:0000058
Nitazoxanide is an alternative antiprotozoal with efficacy comparable to nitroimidazoles in selected studies.
Show evidence (2 references)
PMID:15625030 SUPPORT Other
"Nitazoxanide appears in limited studies to be as effective as tinidazole or metronidazole, and it does not have the bitter taste of nitroimidazoles."
Supports nitazoxanide as a reasonable alternative option.
PMID:18348774 SUPPORT Human Clinical
"Among the 137 children who completed the study (74 given nitazoxanide and 63 given tinidazole), the frequency of parasitological cure following a single dose of tinidazole was significantly higher than that following six doses of nitazoxanide (90.5% v. 78.4%; P<0.05)."
Randomized pediatric trial provides comparative efficacy context for nitazoxanide versus tinidazole.
Paromomycin in pregnancy or nitroimidazole-constrained settings
Action: pharmacotherapy MAXO:0000058
Agent: paromomycin
Paromomycin is a non-absorbed alternative used when systemic nitroimidazoles are less desirable.
Show evidence (1 reference)
PMID:15625030 SUPPORT Other
"A good alternate for use during pregnancy is paromomycin."
Supports paromomycin as a pregnancy-compatible alternative.
Investigational therapy for resistant/refractory giardiasis
Action: pharmacotherapy MAXO:0000058
Repurposed agents are under study for resistant or recurrent disease phenotypes.
Show evidence (2 references)
DOI:10.1128/aac.00731-23 SUPPORT Other
"Fexinidazole and its metabolites were also active against a metronidazole-resistant strain of G. lamblia."
Supports active development of alternatives for resistant cases.
clinicaltrials:NCT02736968 SUPPORT Human Clinical
"This study is designed to compare placebo to once daily doses of 6mg auranofin for adults with amebiasis or giardiasis."
Supports active human trial evaluation of repurposed therapy in giardiasis.
🌍

Environmental Factors

3
Untreated freshwater exposure
Exposure to untreated freshwater increases acquisition risk.
Show evidence (1 reference)
PMID:30020611 SUPPORT Other
"In high-income countries, risk factors for giardiasis include international travel, exposure to untreated freshwater sources, male-male sexual contact, contact with diapered children, recent antibiotic use, and underlying chronic gastrointestinal disease."
Supports untreated freshwater as an environmental risk factor.
Childcare and close-contact fecal-oral exposure
Contact with diapered children and close household/sexual contact contexts increase transmission risk.
Show evidence (1 reference)
PMID:30020611 SUPPORT Other
"In high-income countries, risk factors for giardiasis include international travel, exposure to untreated freshwater sources, male-male sexual contact, contact with diapered children, recent antibiotic use, and underlying chronic gastrointestinal disease."
Supports close-contact transmission-promoting environments.
Water infrastructure failure and rainfall-associated contamination
Outbreaks are associated with treatment failures and rainfall-driven contamination events.
Show evidence (1 reference)
PMID:41280732 SUPPORT Other
"Recreational and drinking water sources were the most commonly implicated, with contamination events often associated with specific incidents or treatment failures, and heavy rainfall suggested as contributing factor to pathogen entry."
Supports infrastructure and weather-linked environmental amplification of risk.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Giardiasis:

Amebiasis Not Yet Curated MONDO:0005644
Overlapping Features Amebic colitis can mimic chronic or recurrent giardiasis-associated bowel symptoms.
Distinguishing Features
  • Amebiasis may present as non-dysenteric amoebic colitis that overlaps symptomatically with IBS-like syndromes.
  • Species-specific stool testing helps discriminate Entamoeba from Giardia.
Show evidence (1 reference)
PMID:17070814 SUPPORT Other
"Although Entamoeba histolytica infections occur predominately in developing regions of the world, clinical diagnosis of amebiasis is often difficult because symptoms of patients with IBS may closely mimic those patients with non-dysenteric amoebic colitis."
Supports amebiasis as a clinically relevant mimic requiring differential diagnosis.
Cryptosporidiosis Not Yet Curated MONDO:0015474
Overlapping Features Another protozoan diarrheal infection with overlapping watery diarrhea phenotypes and waterborne exposure context.
Distinguishing Features
  • Shared waterborne epidemiology may require pathogen-specific stool testing for discrimination.
  • Persistent protozoal diarrhea in immunocompromised hosts should include both Giardia and Cryptosporidium testing.
Show evidence (1 reference)
PMID:41280732 PARTIAL Other
"Giardia and Campylobacter are two key waterborne pathogens and leading agents of gastrointestinal illnesses."
Supports waterborne protozoal differential context; species-level stool diagnostics remain necessary.
Overlapping Features Functional bowel disorders can be misclassified when persistent protozoal infection is not excluded.
Distinguishing Features
  • Giardia can produce recurrent IBS-like symptoms that persist for years.
  • Routine parasitological stool workup helps avoid mislabeling protozoal infection as functional IBS.
Show evidence (2 references)
PMID:17070814 SUPPORT Other
"These IBS-like symptoms can be continuous, intermittent, sporadic or recurrent, sometimes lasting years without correct diagnosis."
Supports diagnostic overlap between chronic giardiasis and IBS.
PMID:17070814 SUPPORT Other
"It is essential that all patients with IBS undergo routine parasitological investigations in order to rule out the presence of protozoan parasites as the causative agents of the clinical signs."
Supports explicit parasitology testing to distinguish giardiasis from IBS.
📊

Related Datasets

3
Analysis of the transcriptomes of Giardia intestinalis assemblages A, B, and E using strand-specific RNA-seq geo:GSE36490
Strand-specific bulk RNA-seq resource profiling trophozoites from multiple Giardia intestinalis assemblages linked to host preference and symptom heterogeneity in giardiasis.
Giardia duodenalis BULK RNA SEQ
Conditions: assemblage A (WB, AS175) assemblage B (GS) assemblage E (P15)
PMID:23555231
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36490
Show evidence (2 references)
GEO:GSE36490 SUPPORT In Vitro
"We have performed strand-specific RNA-seq of trophozoites from four different Giardia intestinalis strains (A=WB and AS175, B=GS, E=P15)."
GEO summary directly supports accession content and parasite-stage context.
PMID:23555231 SUPPORT In Vitro
"Four genetically different isolates were studied (WB (AI), AS175 (AII), P15 (E) and GS (B)) using paired-end, strand-specific RNA-seq."
PMID abstract corroborates multi-assemblage transcriptomic design relevant to Giardia pathogenesis biology.
Steady-state expression of Giardia lamblia transcripts geo:GSE158187
Giardia trophozoite RNA-seq dataset used to quantify steady-state transcript expression and support refined Giardia gene models relevant to parasite biology in giardiasis.
Giardia duodenalis BULK RNA SEQ
Conditions: steady-state trophozoite transcript expression
PMID:35110372
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158187
Show evidence (2 references)
GEO:GSE158187 SUPPORT In Vitro
"RNASequencing and RNA level measurements of G. lamblia transcripts during trophozite stage to compare expression between genes of interest"
GEO summary supports the transcriptomic scope and trophozoite stage.
PMID:35110372 SUPPORT In Vitro
"Using long-read sequencing, we characterize the polyadenylation signal and related sequences surrounding Giardia lamblia cleavage sites for over 2600 genes."
Abstract supports transcript-level molecular characterization aligned with this dataset.
Defining Giardia lamblia cleavage sites geo:GSE168675
Long-read and 3' end sequencing dataset defining mRNA cleavage sites and polyadenylation features in Giardia trophozoites, supporting post-transcriptional mechanism studies relevant to giardiasis.
Giardia duodenalis BULK RNA SEQ
Conditions: 3-prime end and long-read sequencing for cleavage-site mapping
PMID:35110372
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE168675
Show evidence (2 references)
GEO:GSE168675 SUPPORT In Vitro
"3'-end sequencing and Oxford Nanopore Technologies long-read sequencing of trophozoite RNA to define mRNA cleavage sites"
GEO summary directly supports the dataset's sequencing strategy and biological material.
PMID:35110372 SUPPORT In Vitro
"We find that G. lamblia uses an AGURAA poly(A) signal, which differs from the mammalian AAUAAA."
PMID abstract supports disease-relevant molecular findings from cleavage/polyadenylation analyses.
🔬

Clinical Trials

2
NCT02736968 PHASE_II UNKNOWN
Phase IIa randomized placebo-controlled trial of oral auranofin in adults with giardiasis or amebiasis.
Target Phenotypes: Diarrhea
Show evidence (2 references)
clinicaltrials:NCT02736968 SUPPORT Human Clinical
"This is a phase IIa, randomized, placebo-controlled, single-blinded superiority treatment study in males and non-pregnant females, 18 to 65 years of age who are in good health."
Supports interventional adult trial framework for giardiasis treatment evaluation.
clinicaltrials:NCT02736968 SUPPORT Human Clinical
"This study is designed to compare placebo to once daily doses of 6mg auranofin for adults with amebiasis or giardiasis."
Supports direct drug-versus-placebo efficacy evaluation in giardiasis.
NCT06533696 NOT_APPLICABLE UNKNOWN
Pediatric study comparing stool microscopy and ELISA for Giardia diagnosis in symptomatic children.
Target Phenotypes: Diarrhea
Show evidence (1 reference)
clinicaltrials:NCT06533696 SUPPORT Human Clinical
"The present study was done to evaluate the efficacy of Human anti Giardia lamblia antibody (ELISA) kitst in comparison to direct microscopy in the diagnosis of G. lamblia in stool specimens from immunocompetent and immunocompromised children with diarrhea and other gastrointestinal symptoms."
Supports an active diagnostic-method comparison study in pediatric giardiasis.
📚

Literature Summaries

1
Falcon
Disease Characteristics Research Template
Edison Scientific Literature 41 citations 2026-04-04T14:13:43.519561

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Giardiasis
  • MONDO ID: (if available)
  • Category: Infectious

Research Objectives

Please provide a comprehensive research report on Giardiasis covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.


1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Disease Characteristics Report: Giardiasis (Infectious)

Executive summary (current understanding)

Giardiasis is an intestinal protozoal infection caused by Giardia duodenalis (synonyms used in current literature: Giardia lamblia, Giardia intestinalis) that primarily colonizes the proximal small intestine and adheres to the epithelial surface without deep tissue invasion. Infection is acquired predominantly via fecal–oral transmission through contaminated water and food and is facilitated by a low infectious dose and environmentally persistent cysts. Clinical disease ranges from asymptomatic carriage to acute or prolonged diarrheal illness with malabsorption and weight loss; in children, prolonged/recurrent infection is associated with impaired growth and neurocognitive sequelae. (rossi2024protozoaninfectionsacquired pages 21-23, sosnowski2024enterictuftcell pages 52-57)

A 2024 national surveillance analysis from Germany illustrates that giardiasis remains a persistent public-health burden in high-income settings, with both imported and autochthonous transmission and clear age/sex/seasonal patterns. (hommes2024autochthonousandimported pages 1-2)


1. Disease information

1.1 Disease overview

Giardiasis is a gastrointestinal infectious disease caused by the flagellated protozoan Giardia duodenalis (also referred to as G. lamblia/G. intestinalis in many sources). Symptomatic disease commonly presents with diarrhea, abdominal pain/cramps, bloating/flatulence, nausea/vomiting, malabsorption, and weight loss; chronic infection is associated with longer-term sequelae such as growth retardation, iron-deficiency anemia, cognitive impairment, and post-infectious IBS. (rossi2024protozoaninfectionsacquired pages 21-23, sosnowski2024enterictuftcell pages 52-57)

1.2 Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

The requested canonical identifiers (ICD-10/ICD-11, MeSH, MONDO, OMIM, Orphanet) were not present in the retrieved full texts during this tool run, so they cannot be provided with tool-supported citations here. This is a key evidence gap for knowledge base population.

1.3 Synonyms and alternative names (evidence-backed)

  • Giardiasis
  • Giardia duodenalis infection
  • Giardia lamblia infection
  • Giardia intestinalis infection (rossi2024protozoaninfectionsacquired pages 21-23, sosnowski2024enterictuftcell pages 52-57)

1.4 Evidence provenance

The information summarized here is derived from aggregated disease-level resources (systematic reviews, surveillance analyses, cohort studies, and clinical trial registry records), not individual EHR patient records. (hommes2024autochthonousandimported pages 1-2, vicente2024systematicreviewof pages 5-8, gutierrez2024giardialambliarisk pages 1-2)


2. Etiology

2.1 Disease causal factors

Infectious cause: Giardia duodenalis (intestinal protozoan). (rossi2024protozoaninfectionsacquired pages 21-23, sosnowski2024enterictuftcell pages 52-57)

Life stages relevant to disease/transmission: - Trophozoite is the luminal/epithelial-surface stage associated with symptoms. - Cyst is the environmentally resistant, stool-shed infective stage. (rossi2024protozoaninfectionsacquired pages 21-23)

Key transmission enabling characteristics (quantitative): low infectious dose (~10–100 cysts; one estimate notes a single cyst may confer ~2% probability of disease), heavy shedding (one estimate cited ~2.5×10^7 cysts per year from an individual), and prolonged cyst survival in water/food (weeks to months). (rossi2024protozoaninfectionsacquired pages 21-23)

2.2 Risk factors (human)

Household/environmental risk factors (birth cohort, Nicaragua; qPCR-based): - Earthen floors: HR 1.99 (95% CI 1.23–3.20) for first Giardia-associated AGE. - Presence of mice: HR 3.17 (95% CI 1.43–7.00). (gutierrez2024giardialambliarisk pages 6-9, gutierrez2024giardialambliarisk pages 5-6)

Imported vs autochthonous risk patterns (Germany surveillance, 2002–2021): Imported cases were common and predominantly affected adults aged 20–39 years, while autochthonous incidence was highest in young children (<5 years) and males. The authors discuss plausible links of adult male excess to sexual transmission among men who have sex with men (MSM) as a hypothesis requiring further investigation. (hommes2024autochthonousandimported pages 1-2, hommes2024autochthonousandimported pages 5-7)

Food- and water-related exposures: drinking untreated river/spring water and lack of handwashing are described as significant risk factors in the food/water update literature; multiple large waterborne outbreaks implicate municipal water systems. (rossi2024protozoaninfectionsacquired pages 23-24)

2.3 Protective factors (quantitative)

Protective factors (birth cohort, Nicaragua): - Indoor toilet: aHR 0.52 (95% CI 0.29–0.92). - Breastfeeding in the first year: aHR 0.10 (95% CI 0.02–0.57). - Dogs/cats in the home: aHR 0.54 (95% CI 0.33–0.89). - Hand sanitizer (crude): HR 0.22 (95% CI 0.09–0.52). (gutierrez2024giardialambliarisk pages 6-9, gutierrez2024giardialambliarisk pages 1-2)

Context-dependent effect modification: in the same cohort, breastfeeding ≥6 months was associated with higher incidence under very poor household sanitation (no indoor toilet plus earthen floor): HR 7.79 (95% CI 2.07–29.3). (gutierrez2024giardialambliarisk pages 1-2)

2.4 Gene-environment interactions

No human host genetic susceptibility loci or gene–environment interaction findings were available in the retrieved evidence set for this run.


3. Phenotypes (clinical and laboratory)

3.1 Core clinical phenotypes

Common symptomatic disease features include diarrhea, abdominal pain/cramps, bloating/flatulence, nausea/vomiting, malabsorption, and weight loss. (rossi2024protozoaninfectionsacquired pages 21-23, hommes2024autochthonousandimported pages 4-5)

Symptom frequencies (Germany surveillance; autochthonous): diarrhea 80.9%, pain 52.4%, flatulence 24.4%. (hommes2024autochthonousandimported pages 4-5)

Childhood clinical pattern (Nicaragua birth cohort): Giardia-associated AGE was typically mild; median diarrhea duration 5 days (IQR 3–9). Bloody stools were rare (1.0%), and vomiting and fever were less frequent than in non-Giardia AGE (vomiting 19.2% vs 26.3%; fever 31.7% vs 39.3%). (gutierrez2024giardialambliarisk pages 6-9, gutierrez2024giardialambliarisk pages 5-6)

3.2 Quality-of-life impact

Formal QoL instruments (e.g., EQ-5D, SF-36) were not reported in the retrieved evidence excerpts; however, longer-term morbidity (post-infectious syndromes, growth/cognitive impacts) is consistently emphasized in the reviews. (rossi2024protozoaninfectionsacquired pages 21-23, sosnowski2024enterictuftcell pages 52-57)

3.3 Suggested HPO terms

A curated phenotype-to-HPO mapping (with quantitative notes where available) is provided in the artifact below.

Clinical feature (plain language) Evidence-supported details/quantitative notes (if available) Suggested HPO term(s) Suggested LOINC/SNOMED lab concept (optional) Supporting evidence citation IDs
Diarrhea (acute) Core manifestation of giardiasis; in German surveillance, diarrhea was reported in 80.9% of autochthonous cases. In the Nicaraguan birth cohort, Giardia-associated AGE had median diarrhea duration 5 days (IQR 3–9). Diarrhea (HP:0002014); Acute diarrhea (HPO: needs curation) SNOMED CT: Diarrhea (hommes2024autochthonousandimported pages 4-5, gutierrez2024giardialambliarisk pages 5-6)
Diarrhea (prolonged/persistent) Prolonged giardiasis is emphasized in children; persistent/prolonged diarrhea is linked to ongoing carriage and chronic morbidity in cohort/review literature. Chronic diarrhea (HP:0002028); Persistent diarrhea (HPO: needs curation) SNOMED CT: Chronic diarrhea (gutierrez2024giardialambliarisk pages 10-11, rossi2024protozoaninfectionsacquired pages 21-23)
Abdominal pain / cramps Abdominal pain/cramps are common symptomatic features; German surveillance recorded pain in 52.4% of autochthonous cases. Abdominal pain (HP:0002027); Abdominal cramping (HPO: needs curation) SNOMED CT: Abdominal pain (hommes2024autochthonousandimported pages 4-5, rossi2024protozoaninfectionsacquired pages 21-23)
Bloating / flatulence Bloating is repeatedly described in review literature; flatulence occurred in 24.4% of German autochthonous cases. Abdominal bloating (HP:0003270); Flatulence (HP:0012537) SNOMED CT: Abdominal bloating / Flatulence (hommes2024autochthonousandimported pages 4-5, rossi2024protozoaninfectionsacquired pages 21-23)
Nausea / vomiting Nausea and vomiting are recognized manifestations; in the Nicaraguan cohort, vomiting was less common in Giardia-associated AGE than other AGE (19.2% vs 26.3%). Nausea (HP:0002018); Vomiting (HP:0002013) SNOMED CT: Nausea / Vomiting (gutierrez2024giardialambliarisk pages 6-9, rossi2024protozoaninfectionsacquired pages 21-23)
Weight loss Weight loss is a standard clinical feature of symptomatic giardiasis, especially with malabsorption/chronic disease. Weight loss (HP:0001824) SNOMED CT: Weight loss (rossi2024protozoaninfectionsacquired pages 21-23, sosnowski2024enterictuftcell pages 52-57)
Malabsorption Review literature describes malabsorption as a characteristic consequence of intestinal infection and epithelial dysfunction. Malabsorption (HP:0002024) SNOMED CT: Malabsorption syndrome (rossi2024protozoaninfectionsacquired pages 21-23, sosnowski2024enterictuftcell pages 52-57)
Dehydration Mentioned as part of the symptomatic clinical picture in review literature, particularly in diarrheal illness. Dehydration (HP:0001944) SNOMED CT: Dehydration (amorim2024giardíasediagnósticotratamento pages 6-7)
Fever (uncommon) Fever was uncommon in Giardia-associated AGE; cohort data showed fever in 31.7% of Giardia AGE vs 39.3% of non-Giardia AGE, supporting relative infrequency. Fever (HP:0001945) SNOMED CT: Fever (gutierrez2024giardialambliarisk pages 6-9, gutierrez2024giardialambliarisk pages 1-2)
Bloody stool (rare) Bloody stool is uncommon/rare in giardiasis; the Nicaraguan cohort reported blood in stool in 1.0% of Giardia-associated AGE episodes. Hematochezia (HP:0002573); Blood in stool (HP:0002571) SNOMED CT: Hematochezia (gutierrez2024giardialambliarisk pages 6-9, gutierrez2024giardialambliarisk pages 1-2)
Growth retardation / stunting Chronic/recurrent giardiasis in early childhood is associated with growth retardation/stunting in multiple recent reviews and epidemiologic studies. Growth delay (HP:0001510); Short stature (HP:0004322); Stunted growth (HPO: needs curation) (rossi2024protozoaninfectionsacquired pages 21-23, sosnowski2024enterictuftcell pages 52-57)
Cognitive impairment Early-childhood giardiasis is associated with cognitive impairment/intellectual deficits in review literature. Cognitive impairment (HP:0100543); Intellectual disability (HP:0001249) (rossi2024protozoaninfectionsacquired pages 21-23, vicente2024systematicreviewof pages 1-2)
Iron-deficiency anemia Chronic giardiasis has been linked to iron-deficiency anemia in review literature. Iron deficiency anemia (HP:0001891); Anemia (HP:0001903) LOINC: Hemoglobin [Mass/volume] in Blood; Ferritin [Mass/volume] in Serum or Plasma (rossi2024protozoaninfectionsacquired pages 21-23)
Post-infectious IBS Long-term sequelae include post-infectious irritable bowel syndrome; this is specifically noted in recent reviews and model-oriented overview text. Abnormality of the digestive system physiology (HPO: needs curation); Irritable bowel syndrome (HPO: needs curation) SNOMED CT: Irritable bowel syndrome (rossi2024protozoaninfectionsacquired pages 21-23, sosnowski2024enterictuftcell pages 52-57)
Fatigue Post-infectious fatigue is described among longer-term sequelae following giardiasis. Fatigue (HP:0012378) SNOMED CT: Fatigue (sosnowski2024enterictuftcell pages 52-57)
Arthritis Arthritis/post-infectious arthritic complications are reported among sequelae in review/model overview literature. Arthritis (HP:0001369); Arthralgia (HP:0002829) SNOMED CT: Arthritis (sosnowski2024enterictuftcell pages 52-57)

Table: This table maps common clinical features and complications of giardiasis to suggested phenotype ontology terms, with quantitative notes where recent evidence provided them. It is useful as a starting point for disease knowledge base curation and phenotype annotation.


4. Genetic / molecular information (host and pathogen)

4.1 Causal genes

Giardiasis is not a monogenic human disorder; it is an infectious disease. No host causal genes/variants were identified in the retrieved evidence.

4.2 Pathogen genetic structure relevant to epidemiology (assemblages)

The retrieved evidence describes eight Giardia genetic assemblages (A–H), with assemblages A and B having broad host ranges (zoonotic potential) and being most common in humans. (sosnowski2024enterictuftcell pages 52-57)

4.3 Epigenetics / chromosomal abnormalities

Not applicable for human germline inheritance in this context; no relevant evidence retrieved.


5. Environmental information

5.1 Environmental and lifestyle risk factors

Food- and waterborne transmission is strongly supported; cysts have been detected on a broad range of foods, and ready-to-eat salads and unwashed vegetables can be contaminated at nontrivial rates (e.g., 0.5–1.8% contamination of ready-to-eat salads; up to 55% contamination in unwashed vegetables in one setting). The low infectious dose (~10 cysts) implies that incomplete washing may not reliably reduce risk below an infectious threshold. (rossi2024protozoaninfectionsacquired pages 23-24)

5.2 Infectious agent

Causative pathogen: Giardia duodenalis (G. lamblia, G. intestinalis). (rossi2024protozoaninfectionsacquired pages 21-23, sosnowski2024enterictuftcell pages 52-57)


6. Mechanism / pathophysiology (current understanding)

6.1 Causal chain (high-level)

1) Ingestion of infectious cysts (food/water/fecal–oral) → 2) excystation and emergence of trophozoites → 3) colonization/attachment at the duodenal epithelial surface (ventral adhesive disc) without invasion → 4) disruption of intestinal physiology and barrier function with downstream malabsorption and diarrheal symptoms; interactions with mucus and microbiota are implicated in both susceptibility and disease phenotype → 5) in some individuals, prolonged carriage and post-infectious sequelae. (sosnowski2024enterictuftcell pages 52-57)

6.2 Immune and epithelial involvement (conceptual)

The retrieved evidence emphasizes mucosal immune involvement and dysbiosis/inflammation links and highlights that Giardia can perturb epithelial barrier integrity (tight junction-associated processes) and microbiota composition/function, which may contribute to chronic consequences and metabolic perturbations. (sosnowski2024enterictuftcell pages 52-57, klimczak2024theinfluenceof pages 18-19)

Suggested ontology anchors (need curation): - GO Biological Process: “intestinal epithelial barrier maintenance” (GO: needs curation); “inflammatory response” (GO: needs curation) - CL Cell types: intestinal epithelial cell (CL:0000066), goblet cell (CL:0000160), Paneth cell (CL:0000160 needs curation), macrophage (CL:0000235) (sosnowski2024enterictuftcell pages 52-57) - UBERON: small intestine (UBERON:0002108), duodenum (UBERON:0002114) (needs curation; anatomic sites supported conceptually) (sosnowski2024enterictuftcell pages 52-57)


7. Anatomical structures affected

7.1 Organ level

Primary site is the gastrointestinal tract, particularly proximal small intestine/duodenum where trophozoites attach. (sosnowski2024enterictuftcell pages 52-57)

7.2 Tissue/cell level

Intestinal epithelium and associated mucosal immune compartment are key interfaces; barrier function and microbiota interactions are repeatedly emphasized. (sosnowski2024enterictuftcell pages 52-57, klimczak2024theinfluenceof pages 18-19)


8. Temporal development

8.1 Onset

Typically acute/subacute onset after exposure, but many infections are asymptomatic. (sosnowski2024enterictuftcell pages 52-57)

8.2 Progression and course

The clinical course ranges from self-limited diarrheal disease to prolonged infection and post-infectious syndromes. Pediatric burden is concentrated in early life; in a Nicaraguan cohort, incidence peaked at age 12–24 months. (gutierrez2024giardialambliarisk pages 1-2)


9. Inheritance and population

9.1 Epidemiology (recent data)

Germany (national surveillance 2002–2021; published 16 May 2024): - 72,318 cases reported; mean annual incidence 4.4/100,000. - 2002–2019: 69,345 cases; 34.6–35% imported; autochthonous mean annual incidence 3.1/100,000. - Highest incidence in children <5 years (up to 8.5/100,000 in a year) and elevated incidence in adults 20–55; imported cases concentrated in adults 20–39. - Declining trend after 2013 and sharp decline in 2020–21. - Clinical severity: hospitalization was 11.5% among autochthonous cases; three deaths in 2002–19 (0.01%). (hommes2024autochthonousandimported pages 1-2, hommes2024autochthonousandimported pages 2-4)

Global estimates and outbreak burden (review-level): - ~180 million symptomatic infections annually reported in a 2024 food/water update; another source notes symptomatic disease affects ~280 million annually. - >140 waterborne outbreaks (2011–2017) cited; foodborne cases estimated ~23.2 million annually (likely underestimated). (rossi2024protozoaninfectionsacquired pages 21-23, sosnowski2024enterictuftcell pages 52-57)

Pediatric cohort (Nicaragua; published Nov 2024): - Giardia detected in 7.5% of AGE episodes (104/1,385). - 15.6% of children had ≥1 Giardia-associated AGE episode; 36.2% of infected children had recurrent episodes. - Incidence of first Giardia-associated AGE 6.8 per 100 child-years (95% CI 4.5–9.1), peaking at 13.9/100 child-years at 12–24 months. (gutierrez2024giardialambliarisk pages 5-6, gutierrez2024giardialambliarisk pages 1-2)

9.2 Human inheritance

Not applicable (infectious etiology).


10. Diagnostics

10.1 Diagnostic modalities (current practice)

A 2024 systematic review on giardiasis diagnostics highlights the continued central role of microscopy/concentration methods and increasing use of immunoassays and PCR/NAAT, with tradeoffs between cost/infrastructure and analytic performance. (vicente2024systematicreviewof pages 1-2)

Microscopy: widely used; sensitivity limited by intermittent shedding; improved by concentration (e.g., Ritchie) and by collecting multiple stool samples. The review notes direct exam false-negative rate 42% vs 14% for concentration and that collecting three samples across days can raise sensitivity to ~94% vs ~50–70% for a single sample. (vicente2024systematicreviewof pages 10-11)

Performance ranges (compiled across studies): - Direct stool microscopy sensitivity ~34.7–55%, specificity 96–100%. - Concentration methods sensitivity ~65.2–83%. - Antigen detection sensitivity 44–100%, specificity 68–100% (one cited ELISA 95–100% sensitivity and 100% specificity). - Molecular assays sensitivity 58–92%, specificity 56–100% (one cited average 92% sensitivity and 100% specificity). (amal2024epidemiologicalstudyof pages 59-62)

Molecular assays caveats: PCR inhibitors and DNA degradation can yield false negatives; negative PCR does not fully exclude infection. Cost and infrastructure limit adoption in low-resource settings. (vicente2024systematicreviewof pages 10-11, vicente2024systematicreviewof pages 1-2)

10.2 Differential diagnosis and formal diagnostic criteria

Differential diagnosis and formal clinical criteria were not explicitly detailed in the retrieved excerpts; additional guideline retrieval would be needed for a knowledge base entry.


11. Outcome / prognosis

Mortality is generally low; German surveillance reported three acute giardiasis deaths in 2002–2019 (0.01% of specified cases). Morbidity can be substantial via prolonged diarrhea and longer-term sequelae such as growth retardation and cognitive effects. (hommes2024autochthonousandimported pages 2-4, rossi2024protozoaninfectionsacquired pages 21-23)


12. Treatment

12.1 Standard pharmacotherapy

A 2024 treatment update describes 5-nitroimidazoles as the most effective therapies, specifically naming metronidazole and tinidazole: “El tratamiento más eficaz son los 5-nitroimidazoles, en concreto el metronidazol y el tinidazol.” Tinidazole’s advantage is single-dose administration. (sanchez2024actualizacióndeltratamiento pages 1-6, sanchez2024actualizacióndeltratamiento pages 6-12)

Other agents described as alternative/second-line options (particularly after treatment failure) include albendazole/mebendazole, nitazoxanide, furazolidone, paromomycin, chloroquine, and quinacrine/mepacrine. (sanchez2024actualizacióndeltratamiento pages 1-6, thakur2024perspectivesonthe pages 4-6)

12.2 Refractory/resistant giardiasis (recent synthesis)

Recent treatment-oriented literature emphasizes increasing refractory disease: one cited study reported 5.8% failure across regimens involving nitroimidazoles, and another series documented metronidazole-refractory cases rising from 15% to >40% (2008–2013). Quinacrine is described as an option used in some countries for metronidazole non-responders but limited by adverse effects including vomiting and psychosis. (thakur2024perspectivesonthe pages 4-6)

Combination therapy is referenced, including metronidazole + albendazole as a combined approach discussed in the 2024 treatment update. (sanchez2024actualizacióndeltratamiento pages 1-6)

12.3 Emerging / experimental therapies and clinical trials

Auranofin (repurposing; Phase IIa RCT): ClinicalTrials.gov NCT02736968 (sponsor NIAID) is a completed, randomized, placebo-controlled Phase IIa trial. Giardiasis dosing was auranofin 6 mg orally once daily for 5 days. Primary endpoints included diarrhea resolution (<3 loose stools/24h) by Day 5 plus parasitological response (negative microscopy and/or antigen). Results were submitted 2022-11-17 and first posted 2023-01-26 in the registry, but outcome values were not present in the retrieved text chunks for this report. (NCT02736968 chunk 1, NCT02736968 chunk 2)

12.4 Suggested MAXO terms (needs curation)

  • Antiprotozoal therapy (MAXO: needs curation)
  • Oral metronidazole therapy (MAXO: needs curation)
  • Oral tinidazole therapy (MAXO: needs curation)
  • Stool diagnostic testing / NAAT (MAXO: needs curation)

13. Prevention

13.1 Primary prevention (WASH, food/water)

Key prevention principles supported by the evidence include improving sanitation and hygiene (handwashing), ensuring safe drinking water, and reducing food contamination. The low infectious dose (≈10 cysts) and prolonged environmental survival amplify the importance of water treatment and safe food handling. (sosnowski2024enterictuftcell pages 52-57, rossi2024protozoaninfectionsacquired pages 23-24)

Quantitative foodborne contamination and QMRA data in a 2024 update include: ready-to-eat salad contamination 0.5–1.8% in some studies; unwashed vegetables up to 55% in one setting; QMRA annual infection risk estimate 0.36 and 1.0% probability of illness from locally grown vegetables (as cited). (rossi2024protozoaninfectionsacquired pages 23-24)

13.2 Secondary prevention (early detection)

Use of more sensitive tests (antigen assays and PCR/NAAT) is recommended when symptoms persist despite negative microscopy, and collecting multiple stool specimens improves diagnostic sensitivity. (vicente2024systematicreviewof pages 10-11, vicente2024systematicreviewof pages 1-2)

13.3 Tertiary prevention (preventing complications)

Cohort evidence suggests modifiable household factors associated with reduced childhood burden (indoor toilet; breastfeeding in first year) and supports integrated public-health strategies that reduce early-life infection risk and recurrence. (gutierrez2024giardialambliarisk pages 1-2)


14. Other species / natural disease (One Health)

Giardia infects multiple mammalian hosts, including humans, dogs, cats, cattle and rodents, and zoonotic assemblages A and B have broad host ranges. Environmental contamination routes and animal reservoirs are supported by genotyping links (e.g., assemblage B shared between humans, a dog, and lettuce; beavers implicated in waterborne outbreaks). (sosnowski2024enterictuftcell pages 52-57, rossi2024protozoaninfectionsacquired pages 23-24)


15. Model organisms

A commonly used experimental model is Giardia muris infection in mice; the retrieved evidence notes this murine strain has been used experimentally since the 1960s and has a similar life cycle to G. duodenalis. Germ-free and conventional mouse models are used to study host–microbial dynamics and immune responses. (sosnowski2024enterictuftcell pages 52-57)


Key structured summary tables

Cross-domain key facts table

Domain Key findings Best supporting source (DOI/URL, year) Evidence citation ID
Pathogen / names Giardiasis is caused by the intestinal protozoan Giardia duodenalis; common synonyms in the retrieved literature include G. lamblia and G. intestinalis. Human-infecting assemblages are mainly A and B; the parasite colonizes the proximal small intestine and attaches without mucosal invasion. Gutiérrez & Bartelt, Curr Trop Med Rep (2024), https://doi.org/10.1007/s40475-024-00314-2; Hatam-Nahavandi et al., Gut Pathog (2024), https://doi.org/10.1186/s13099-024-00666-0 (sosnowski2024enterictuftcell pages 52-57, rossi2024protozoaninfectionsacquired pages 21-23)
Transmission / infectious dose / shedding / survival Food- and waterborne transmission is central. Infectious dose is low at about 10–100 cysts; one estimate gives a single cyst about a 2% probability of causing disease. Cysts can survive weeks to months in water/food, tolerate low temperatures, and their small size (8–12 μm) can allow passage through sand filters. One study cited in the review estimated ~2.5×10^7 cysts shed annually by one individual. Rossi et al., preprint (2024), https://doi.org/10.20944/preprints202403.1207.v1 (rossi2024protozoaninfectionsacquired pages 21-23)
Key clinical manifestations / sequelae Typical manifestations: diarrhea, bloating, abdominal cramps/pain, nausea, vomiting, malabsorption, and weight loss. Important long-term sequelae reported across reviews include growth retardation/stunting, iron-deficiency anemia, cognitive impairment, post-infectious irritable bowel syndrome, fatigue, and arthritis. In German surveillance, common autochthonous-case symptoms were diarrhea 80.9%, pain 52.4%, and flatulence 24.4%. Hommes et al., Eurosurveillance (2024), https://doi.org/10.2807/1560-7917.es.2024.29.20.2300509; Rossi et al. (2024), https://doi.org/10.20944/preprints202403.1207.v1 (hommes2024autochthonousandimported pages 4-5, rossi2024protozoaninfectionsacquired pages 21-23)
Epidemiology: global burden Review-level estimates in the retrieved evidence report ~180 million symptomatic infections annually worldwide; another retrieved source notes symptomatic disease affects ~280 million people annually. Giardiasis was ranked 11th in the FAO/WHO intestinal parasite risk list; >140 waterborne outbreaks were noted for 2011–2017, and ~23.2 million foodborne cases annually were cited as likely underestimated. Rossi et al., preprint (2024), https://doi.org/10.20944/preprints202403.1207.v1 (rossi2024protozoaninfectionsacquired pages 21-23, sosnowski2024enterictuftcell pages 52-57)
Epidemiology: Germany surveillance Germany reported 72,318 cases from 2002–2021, mean annual incidence 4.4/100,000. From 2002–2019, 69,345 cases were reported; 34.6–35% were imported and autochthonous incidence averaged 3.1/100,000. Highest incidence occurred in young children (<5 years) and in adults 20–39 years for imported cases. Incidence declined after 2013 and dropped sharply in 2020–2021. Hommes et al., Eurosurveillance (2024), https://doi.org/10.2807/1560-7917.es.2024.29.20.2300509 (hommes2024autochthonousandimported pages 1-2, hommes2024autochthonousandimported pages 2-4)
Diagnostics: microscopy / concentration Microscopy remains widely used and practical, but sensitivity is limited by intermittent shedding and operator dependence. Reported ranges from the retrieved evidence: direct stool microscopy sensitivity ~34.7–55% with specificity 96–100%; stool concentration methods improve sensitivity to ~65.2–83%. Collecting three stools across days can raise sensitivity to ~94% vs ~50–70% for a single sample. In Vicente et al., many microscopy studies reported sensitivity 60–89% and specificity often high. Vicente et al., Diagnostics (2024), https://doi.org/10.3390/diagnostics14040364 (vicente2024systematicreviewof pages 5-8, vicente2024systematicreviewof pages 10-11, amal2024epidemiologicalstudyof pages 59-62)
Diagnostics: antigen tests / ELISA / ICA Antigen tests are generally more sensitive than routine microscopy and faster to run. Reported ranges in retrieved evidence: antigen detection sensitivity 44–100% and specificity 68–100%; one GSA65 ELISA reported 95–100% sensitivity and 100% specificity and detected ~30% more cases than microscopy. In Vicente et al., immunoassays commonly showed sensitivity 60–89% and specificity 80–99%, while RIDAQUICK immunochromatography often showed sensitivity 81–100% and specificity 81–100%. Vicente et al., Diagnostics (2024), https://doi.org/10.3390/diagnostics14040364 (vicente2024systematicreviewof pages 5-8, vicente2024systematicreviewof pages 8-10, amal2024epidemiologicalstudyof pages 59-62)
Diagnostics: PCR / NAAT Molecular assays (PCR/qPCR/NAAT) generally provide the highest sensitivity/specificity in the retrieved evidence, but performance varies by target and stool inhibitors can cause false negatives. Reported ranges: molecular sensitivity 58–92% and specificity 56–100%; one cited study reported average 92% sensitivity and 100% specificity. Vicente et al. summarize many molecular studies with 90–99% sensitivity in 32% of articles and 100% sensitivity in 24% of articles. Vicente et al., Diagnostics (2024), https://doi.org/10.3390/diagnostics14040364 (vicente2024systematicreviewof pages 5-8, vicente2024systematicreviewof pages 10-11, amal2024epidemiologicalstudyof pages 59-62)
Treatments: first-line and alternatives First-line therapy in the retrieved 2024 treatment reviews is the 5-nitroimidazole class, especially metronidazole and tinidazole; tinidazole has the convenience of single-dose treatment. Alternatives/second-line options mentioned include albendazole, mebendazole, nitazoxanide, furazolidone, paromomycin, quinacrine/mepacrine, chloroquine, and secnidazole. Sánchez (2024), source retrieved in review corpus; Thakur et al. (2024), https://doi.org/10.5772/intechopen.1005559 (sanchez2024actualizacióndeltratamiento pages 1-6, thakur2024perspectivesonthe pages 4-6, sanchez2024actualizacióndeltratamiento pages 6-12)
Treatments: refractory / resistance Drug-refractory disease is increasingly recognized. Retrieved evidence cites metronidazole treatment failure in 5.8% in one study and reports of metronidazole-refractory cases increasing from 15% to >40% between 2008–2013 in another series. Quinacrine is used in some countries for metronidazole-refractory cases but is limited by adverse effects including vomiting and psychosis. Combination therapy after nitroimidazole failure is referenced; metronidazole + albendazole is specifically identified in a 2024 treatment review. Thakur et al. (2024), https://doi.org/10.5772/intechopen.1005559; Sánchez (2024) (thakur2024perspectivesonthe pages 4-6, thakur2024perspectivesonthe pages 15-17, sanchez2024actualizacióndeltratamiento pages 1-6)
Emerging / trial therapy Auranofin has reached clinical testing. NCT02736968 was a completed Phase IIa randomized, single-blinded, placebo-controlled trial sponsored by NIAID; giardiasis dosing was 6 mg orally once daily for 5 days. Primary outcomes included clinical diarrhea resolution and parasitological response by Day 5; results were posted to ClinicalTrials.gov in 2023, but the retrieved record excerpts did not include outcome values. ClinicalTrials.gov NCT02736968 (first posted 2016; results posted 2023), https://clinicaltrials.gov/study/NCT02736968 (NCT02736968 chunk 1, NCT02736968 chunk 2)
Prevention / protective factors Prevention themes in the retrieved evidence center on safe water, sanitation, hygiene, and limiting food/water exposure. In the Nicaraguan birth cohort, protective factors for first Giardia-associated AGE included an indoor toilet (aHR 0.52, 95% CI 0.29–0.92), breastfeeding in the first year (aHR 0.10, 95% CI 0.02–0.57), hand sanitizer use (HR 0.22, 95% CI 0.09–0.52), and household dogs/cats (aHR 0.54, 95% CI 0.33–0.89). Risk factors included earthen floors (HR 1.99, 95% CI 1.23–3.20), mice in the house (HR 3.17, 95% CI 1.43–7.00), and poor sanitation. Gutiérrez et al., PLOS Negl Trop Dis (2024), https://doi.org/10.1371/journal.pntd.0012230 (gutierrez2024giardialambliarisk pages 6-9, gutierrez2024giardialambliarisk pages 5-6, gutierrez2024giardialambliarisk pages 1-2)
Pediatric burden / age distribution In the Nicaraguan birth cohort, 104/1,385 AGE episodes (7.5%) were Giardia-positive; 69/443 children (15.6%) had ≥1 episode and 36.2% of infected children had recurrent episodes. Incidence of first Giardia-associated AGE was 6.8/100 child-years overall and peaked at 13.9/100 child-years in ages 12–24 months. Episodes were typically mild, with blood in stool uncommon and lower vomiting/fever frequencies than AGE without Giardia. Gutiérrez et al., PLOS Negl Trop Dis (2024), https://doi.org/10.1371/journal.pntd.0012230 (gutierrez2024giardialambliarisk pages 5-6, gutierrez2024giardialambliarisk pages 1-2)
One Health / zoonotic aspects Assemblages A and B support both anthroponotic and zoonotic transmission; human cases with other assemblages (C–F) are also reported in the review literature. Water studies in MENA found G. duodenalis prevalence of 37.7% across sampled water resources, with assemblage A frequent. Reviews emphasize overlap among human, animal, and environmental reservoirs and underrecognition of waterborne transmission. Rossi et al. (2024), https://doi.org/10.20944/preprints202403.1207.v1; Ayed et al., J Water Health (2024), https://doi.org/10.2166/wh.2024.107 (rossi2024protozoaninfectionsacquired pages 21-23)
Model organisms / experimental systems Common model systems in the retrieved evidence include Giardia muris mouse infection models and gnotobiotic/germ-free mice susceptible to diverse human-pathogenic Giardia assemblages. These models are used to study mucosal immunity, microbiota dependence, vaccination, and epithelial responses; other cited systems include epithelial monolayers and some veterinary/rodent models. Ihara et al., Infect Immun (2024), https://doi.org/10.1128/iai.00065-24; Sosnowski (2024) (sosnowski2024enterictuftcell pages 52-57, bretzenberger2024giardiosebeihund pages 38-42)

Table: This table compiles compact, high-confidence findings on giardiasis from the retrieved evidence base, including transmission biology, burden, diagnostics, treatment, prevention, and One Health/model-system context. It is designed as a quick-reference summary with quantitative values and direct evidence IDs for traceability.


Evidence gaps and curation flags (important for knowledge base use)

1) Canonical disease identifiers (ICD-10/11, MeSH, MONDO, OMIM/Orphanet) were not retrievable with citable evidence in this run. 2) PMID-preferred primary literature: Several retrieved sources provide DOIs/URLs and summarize primary studies, but PMIDs were not consistently available in the captured excerpts. 3) Mechanism ontology mappings (GO/CL/UBERON): only partial, high-confidence mappings can be suggested; many require curation. 4) Auranofin trial outcomes: registry record confirms design and endpoints with results posted in 2023, but outcome values were not available in retrieved text chunks.


Recent developments and expert analysis (2023–2024 prioritized)

  • Diagnostics: 2024 systematic review highlights that microscopy remains widely used but that immunoassays and PCR/NAAT offer higher sensitivity, with implementation constrained by cost/infrastructure in many regions; multi-sample collection is emphasized as a practical sensitivity-improving strategy. (vicente2024systematicreviewof pages 10-11, vicente2024systematicreviewof pages 1-2)
  • Epidemiology in high-income settings: 2024 Germany surveillance analysis demonstrates substantial autochthonous transmission (not just travel-related) and calls for investigation of dietary/behavioral/environmental drivers, including potential sexual transmission networks. (hommes2024autochthonousandimported pages 1-2, hommes2024autochthonousandimported pages 5-7)
  • Childhood risk/protection: 2024 Nicaraguan birth-cohort data provide granular hazard ratios linking household sanitation and breastfeeding to disease burden, supporting targeted WASH and maternal/infant interventions. (gutierrez2024giardialambliarisk pages 1-2)
  • Therapeutics: 2024 treatment reviews emphasize decades-old drug armamentarium, emerging refractory disease, and continued exploration of repurposed candidates such as auranofin. (thakur2024perspectivesonthe pages 4-6, NCT02736968 chunk 1)

References

  1. (rossi2024protozoaninfectionsacquired pages 21-23): Franca Rossi, Carmela Amadoro, Serena Santonicola, Lucio Marino, and Giampaolo Colavita. Protozoan infections acquired from food or drinking water: an update. Mar 2024. URL: https://doi.org/10.20944/preprints202403.1207.v1, doi:10.20944/preprints202403.1207.v1.

  2. (sosnowski2024enterictuftcell pages 52-57): OS Sosnowski. Enteric tuft cell responses and host-microbial dynamics during giardia muris infection. Unknown journal, 2024.

  3. (hommes2024autochthonousandimported pages 1-2): Franziska Hommes, Achim Dörre, Susanne C. Behnke, Klaus Stark, and Mirko Faber. Autochthonous and imported giardiasis cases: an analysis of two decades of national surveillance data, germany, 2002 to 2021. Eurosurveillance, May 2024. URL: https://doi.org/10.2807/1560-7917.es.2024.29.20.2300509, doi:10.2807/1560-7917.es.2024.29.20.2300509. This article has 5 citations and is from a domain leading peer-reviewed journal.

  4. (vicente2024systematicreviewof pages 5-8): Bruno Vicente, Anna De Freitas, Marcus Freitas, and Victor Midlej. Systematic review of diagnostic approaches for human giardiasis: unveiling optimal strategies. Diagnostics, 14:364, Feb 2024. URL: https://doi.org/10.3390/diagnostics14040364, doi:10.3390/diagnostics14040364. This article has 30 citations.

  5. (gutierrez2024giardialambliarisk pages 1-2): Lester Gutiérrez, Nadja A. Vielot, Roberto Herrera, Yaoska Reyes, Christian Toval-Ruíz, Patricia Blandón, Rebecca J. Rubinstein, Javier Mora, Luther A. Bartelt, Filemón Bucardo, Sylvia Becker-Dreps, and Samuel Vilchez. Giardia lamblia risk factors and burden in children with acute gastroenteritis in a nicaraguan birth cohort. PLOS Neglected Tropical Diseases, 18:e0012230, Nov 2024. URL: https://doi.org/10.1371/journal.pntd.0012230, doi:10.1371/journal.pntd.0012230. This article has 4 citations and is from a domain leading peer-reviewed journal.

  6. (gutierrez2024giardialambliarisk pages 6-9): Lester Gutiérrez, Nadja A. Vielot, Roberto Herrera, Yaoska Reyes, Christian Toval-Ruíz, Patricia Blandón, Rebecca J. Rubinstein, Javier Mora, Luther A. Bartelt, Filemón Bucardo, Sylvia Becker-Dreps, and Samuel Vilchez. Giardia lamblia risk factors and burden in children with acute gastroenteritis in a nicaraguan birth cohort. PLOS Neglected Tropical Diseases, 18:e0012230, Nov 2024. URL: https://doi.org/10.1371/journal.pntd.0012230, doi:10.1371/journal.pntd.0012230. This article has 4 citations and is from a domain leading peer-reviewed journal.

  7. (gutierrez2024giardialambliarisk pages 5-6): Lester Gutiérrez, Nadja A. Vielot, Roberto Herrera, Yaoska Reyes, Christian Toval-Ruíz, Patricia Blandón, Rebecca J. Rubinstein, Javier Mora, Luther A. Bartelt, Filemón Bucardo, Sylvia Becker-Dreps, and Samuel Vilchez. Giardia lamblia risk factors and burden in children with acute gastroenteritis in a nicaraguan birth cohort. PLOS Neglected Tropical Diseases, 18:e0012230, Nov 2024. URL: https://doi.org/10.1371/journal.pntd.0012230, doi:10.1371/journal.pntd.0012230. This article has 4 citations and is from a domain leading peer-reviewed journal.

  8. (hommes2024autochthonousandimported pages 5-7): Franziska Hommes, Achim Dörre, Susanne C. Behnke, Klaus Stark, and Mirko Faber. Autochthonous and imported giardiasis cases: an analysis of two decades of national surveillance data, germany, 2002 to 2021. Eurosurveillance, May 2024. URL: https://doi.org/10.2807/1560-7917.es.2024.29.20.2300509, doi:10.2807/1560-7917.es.2024.29.20.2300509. This article has 5 citations and is from a domain leading peer-reviewed journal.

  9. (rossi2024protozoaninfectionsacquired pages 23-24): Franca Rossi, Carmela Amadoro, Serena Santonicola, Lucio Marino, and Giampaolo Colavita. Protozoan infections acquired from food or drinking water: an update. Mar 2024. URL: https://doi.org/10.20944/preprints202403.1207.v1, doi:10.20944/preprints202403.1207.v1.

  10. (hommes2024autochthonousandimported pages 4-5): Franziska Hommes, Achim Dörre, Susanne C. Behnke, Klaus Stark, and Mirko Faber. Autochthonous and imported giardiasis cases: an analysis of two decades of national surveillance data, germany, 2002 to 2021. Eurosurveillance, May 2024. URL: https://doi.org/10.2807/1560-7917.es.2024.29.20.2300509, doi:10.2807/1560-7917.es.2024.29.20.2300509. This article has 5 citations and is from a domain leading peer-reviewed journal.

  11. (gutierrez2024giardialambliarisk pages 10-11): Lester Gutiérrez, Nadja A. Vielot, Roberto Herrera, Yaoska Reyes, Christian Toval-Ruíz, Patricia Blandón, Rebecca J. Rubinstein, Javier Mora, Luther A. Bartelt, Filemón Bucardo, Sylvia Becker-Dreps, and Samuel Vilchez. Giardia lamblia risk factors and burden in children with acute gastroenteritis in a nicaraguan birth cohort. PLOS Neglected Tropical Diseases, 18:e0012230, Nov 2024. URL: https://doi.org/10.1371/journal.pntd.0012230, doi:10.1371/journal.pntd.0012230. This article has 4 citations and is from a domain leading peer-reviewed journal.

  12. (amorim2024giardíasediagnósticotratamento pages 6-7): Marcelo Fagundes Amorim, Gabriel Braga de Castro, Pedro Henrique Santos Victoria, and Isabela Innecco Arêas. Giardíase: diagnóstico, tratamento e abordagens multidisciplinares. Revista Ibero-Americana de Humanidades, Ciências e Educação, 10:498-504, Oct 2024. URL: https://doi.org/10.51891/rease.v10i10.15915, doi:10.51891/rease.v10i10.15915. This article has 0 citations.

  13. (vicente2024systematicreviewof pages 1-2): Bruno Vicente, Anna De Freitas, Marcus Freitas, and Victor Midlej. Systematic review of diagnostic approaches for human giardiasis: unveiling optimal strategies. Diagnostics, 14:364, Feb 2024. URL: https://doi.org/10.3390/diagnostics14040364, doi:10.3390/diagnostics14040364. This article has 30 citations.

  14. (klimczak2024theinfluenceof pages 18-19): Sylwia Klimczak, Kacper Packi, Alicja Rudek, Sylwia Wenclewska, Marcin Kurowski, Daniela Kurczabińska, and Agnieszka Śliwińska. The influence of the protozoan giardia lamblia on the modulation of the immune system and alterations in host glucose and lipid metabolism. International Journal of Molecular Sciences, 25:8627, Aug 2024. URL: https://doi.org/10.3390/ijms25168627, doi:10.3390/ijms25168627. This article has 24 citations.

  15. (hommes2024autochthonousandimported pages 2-4): Franziska Hommes, Achim Dörre, Susanne C. Behnke, Klaus Stark, and Mirko Faber. Autochthonous and imported giardiasis cases: an analysis of two decades of national surveillance data, germany, 2002 to 2021. Eurosurveillance, May 2024. URL: https://doi.org/10.2807/1560-7917.es.2024.29.20.2300509, doi:10.2807/1560-7917.es.2024.29.20.2300509. This article has 5 citations and is from a domain leading peer-reviewed journal.

  16. (vicente2024systematicreviewof pages 10-11): Bruno Vicente, Anna De Freitas, Marcus Freitas, and Victor Midlej. Systematic review of diagnostic approaches for human giardiasis: unveiling optimal strategies. Diagnostics, 14:364, Feb 2024. URL: https://doi.org/10.3390/diagnostics14040364, doi:10.3390/diagnostics14040364. This article has 30 citations.

  17. (amal2024epidemiologicalstudyof pages 59-62): B Amal and H Ghadir. Epidemiological study of human giardiasis at the level from the mila region correlation with parameters weather. Unknown journal, 2024.

  18. (sanchez2024actualizacióndeltratamiento pages 1-6): B Cabré Sánchez. Actualización del tratamiento de giardiasis. Unknown journal, 2024.

  19. (sanchez2024actualizacióndeltratamiento pages 6-12): B Cabré Sánchez. Actualización del tratamiento de giardiasis. Unknown journal, 2024.

  20. (thakur2024perspectivesonthe pages 4-6): Sarika Thakur, Alka Sharma, Reena Negi, Ram Gopal Nitharwal, and Inderjeet Kaur. Perspectives on the drug discovery of intestinal protozoan parasites. Infectious Diseases, Jun 2024. URL: https://doi.org/10.5772/intechopen.1005559, doi:10.5772/intechopen.1005559. This article has 0 citations and is from a peer-reviewed journal.

  21. (NCT02736968 chunk 1): Auranofin for Giardia Protozoa. National Institute of Allergy and Infectious Diseases (NIAID). 2016. ClinicalTrials.gov Identifier: NCT02736968

  22. (NCT02736968 chunk 2): Auranofin for Giardia Protozoa. National Institute of Allergy and Infectious Diseases (NIAID). 2016. ClinicalTrials.gov Identifier: NCT02736968

  23. (vicente2024systematicreviewof pages 8-10): Bruno Vicente, Anna De Freitas, Marcus Freitas, and Victor Midlej. Systematic review of diagnostic approaches for human giardiasis: unveiling optimal strategies. Diagnostics, 14:364, Feb 2024. URL: https://doi.org/10.3390/diagnostics14040364, doi:10.3390/diagnostics14040364. This article has 30 citations.

  24. (thakur2024perspectivesonthe pages 15-17): Sarika Thakur, Alka Sharma, Reena Negi, Ram Gopal Nitharwal, and Inderjeet Kaur. Perspectives on the drug discovery of intestinal protozoan parasites. Infectious Diseases, Jun 2024. URL: https://doi.org/10.5772/intechopen.1005559, doi:10.5772/intechopen.1005559. This article has 0 citations and is from a peer-reviewed journal.

  25. (bretzenberger2024giardiosebeihund pages 38-42): J Bretzenberger. Giardiose bei hund und katze: risikofaktoren und therapeutische optionen–eine literaturübersicht. Unknown journal, 2024.

{ }

Source YAML

click to show
name: Giardiasis
creation_date: '2026-03-02T20:53:58Z'
updated_date: '2026-04-11T01:06:52Z'
category: Infectious
description: >-
  Giardiasis is an intestinal protozoal infection caused by Giardia duodenalis,
  characterized by acute or chronic diarrheal illness, malabsorption, and
  potential post-infectious gastrointestinal sequelae.
disease_term:
  preferred_term: giardiasis
  term:
    id: MONDO:0001103
    label: giardiasis
parents:
- parasitic intestinal disorder
- protozoan infectious disease
synonyms:
- Giardia infection
- Intestinal giardiasis
classifications:
  harrisons_chapter:
  - classification_value: infectious disease
    evidence:
    - reference: PMID:30020611
      reference_title: "Giardiasis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Giardiasis, caused by the protozoan parasite Giardia duodenalis, is one of the most common treatable causes of gastroenteritis worldwide, with a burden higher in low-income countries."
      explanation: Supports classification as an infectious gastroenteric disease.
  - classification_value: parasitic infectious disease
    evidence:
    - reference: PMID:30020611
      reference_title: "Giardiasis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Giardiasis, caused by the protozoan parasite Giardia duodenalis, is one of the most common treatable causes of gastroenteritis worldwide, with a burden higher in low-income countries."
      explanation: Supports classification as a protozoan parasitic disorder.
definitions:
- name: Clinical case framing for giardiasis
  definition_type: CASE_DEFINITION
  description: >-
    Giardiasis is a protozoal gastrointestinal infection with clinical spectra
    ranging from asymptomatic carriage to acute or chronic diarrheal disease.
  scope: Clinical framing for symptomatic and asymptomatic Giardia infection
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating; however, asymptomatic colonization is also common."
    explanation: Supports a broad clinical case definition that includes both symptomatic disease and asymptomatic carriage.
  - reference: PMID:37764167
    reference_title: "The Gut-Wrenching Effects of Cryptosporidiosis and Giardiasis in Children."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The severity of the symptoms and clinical manifestations in children may vary from asymptomatic to life-threatening depending on the Cryptosporidium species/G. duodenalis strains and the resulting complex stepwise interactions between the parasite, the host nutritional and immunologic status, and the gut microbiome profile."
    explanation: Adds independent pediatric-focused support for broad clinical severity spectrum from asymptomatic to severe disease.
- name: Stool-based diagnostic confirmation framework
  definition_type: DIAGNOSTIC_CRITERIA
  description: >-
    Diagnosis can be supported by stool antigen immunoassay and repeated stool
    microscopy when early samples are negative after exposure.
  scope: Routine diagnosis of suspected giardiasis after relevant exposure
  evidence:
  - reference: PMID:2674196
    reference_title: "Stool diagnosis of giardiasis using a commercially available enzyme immunoassay to detect Giardia-specific antigen 65 (GSA 65)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Its sensitivity and specificity were 96 and 100%, respectively, while the sensitivity and specificity of O&P examination were 74 and 100%, respectively."
    explanation: Supports high diagnostic performance of stool antigen immunoassay relative to microscopy.
  - reference: PMID:68190
    reference_title: "Prepatency of giardiasis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A practical conclusion was that, in suspected cases of giardiasis with negative stool findings during the first 3 wk after possible exposure to Giardia, examination of repeated faecal samples is still effective in confirming the diagnosis."
    explanation: Supports repeated stool testing when initial early examinations are negative.
has_subtypes:
- name: Acute symptomatic giardiasis
  classification: clinical_course
  description: Predominantly acute diarrheal illness after Giardia exposure.
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating; however, asymptomatic colonization is also common."
    explanation: Supports an acute symptomatic phenotype subtype.
- name: Chronic giardiasis with malabsorption
  classification: clinical_course
  description: Persistent infection phenotype associated with malabsorption and weight loss.
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In some patients, a chronic infection may lead to malabsorption and weight loss."
    explanation: Supports a chronic malabsorptive subtype.
  - reference: PMID:35250996
    reference_title: "Mucosal Defense Against Giardia at the Intestinal Epithelial Cell Interface."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Chronic G. duodenalis infections cause a malabsorption syndrome that may lead to failure to thrive and/or stunted growth, especially in children in developing countries."
    explanation: Provides independent support that chronic infection can progress to clinically significant malabsorptive and growth-impacting disease.
- name: Refractory or treatment-resistant giardiasis
  classification: treatment_response
  description: Cases with persistent infection despite standard nitroimidazole therapy.
  evidence:
  - reference: DOI:10.1128/aac.00731-23
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Fexinidazole and its metabolites were also active against a metronidazole-resistant strain of G. lamblia."
    explanation: Supports existence of metronidazole-resistant/refractory disease context.
infectious_agent:
- name: Giardia duodenalis
  infectious_agent_term:
    preferred_term: Giardia duodenalis
    term:
      id: NCBITaxon:5741
      label: Giardia duodenalis
  description: >-
    Primary protozoan etiologic agent of human giardiasis (syn. Giardia
    intestinalis, Giardia lamblia); other named Giardia species are largely
    host-adapted to non-human taxa.
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Giardiasis, caused by the protozoan parasite Giardia duodenalis, is one of the most common treatable causes of gastroenteritis worldwide, with a burden higher in low-income countries."
    explanation: Supports Giardia duodenalis as the core infectious agent.
  - reference: PMID:31630759
    reference_title: "Molecular epidemiology of giardiasis from a veterinary perspective."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A total of eight Giardia species are accepted. These include: Giardia duodenalis (syn. Giardia intestinalis and Giardia lamblia), which infects humans and animals, Giardia agilis, Giardia ardeae, Giardia psittaci, Giardia muris, Giardia microti, Giardia peramelis and G. cricetidarum, which infect non-human hosts including amphibians, birds, rodents and marsupials."
    explanation: Supports that human giardiasis is attributed to G. duodenalis, while other Giardia species are non-human host-adapted.
  - reference: PMID:29225147
    reference_title: "Host specificity in the Giardia duodenalis species complex."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Assemblages display various degree of host specificity, with Assemblages A and B occurring in humans and many other hosts, Assemblage C and D in canids, Assemblage E in hoofed animals, Assemblage F in cats, Assemblage G in rodents, and Assemblage H in pinnipeds."
    explanation: Clarifies that human infections are concentrated in specific G. duodenalis assemblages rather than distinct non-duodenalis species.
transmission:
- name: Waterborne transmission
  description: Acquisition through exposure to contaminated recreational or drinking water.
  evidence:
  - reference: PMID:41280732
    reference_title: "Giardia and Campylobacter: Fifteen years (2010-2024) of waterborne outbreaks in Europe."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Giardia and Campylobacter are two key waterborne pathogens and leading agents of gastrointestinal illnesses."
    explanation: Supports waterborne transmission as a major route for giardiasis.
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In high-income countries, risk factors for giardiasis include international travel, exposure to untreated freshwater sources, male-male sexual contact, contact with diapered children, recent antibiotic use, and underlying chronic gastrointestinal disease."
    explanation: Supports untreated freshwater exposure as a clinically important route of acquisition.
- name: Person-to-person fecal-oral transmission
  description: Transmission through close-contact settings including sexual and childcare-associated exposure.
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In high-income countries, risk factors for giardiasis include international travel, exposure to untreated freshwater sources, male-male sexual contact, contact with diapered children, recent antibiotic use, and underlying chronic gastrointestinal disease."
    explanation: Supports close-contact fecal-oral transmission contexts.
prevalence:
- population: Global
  notes: High global burden with disproportionate impact in low-income settings.
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Giardiasis, caused by the protozoan parasite Giardia duodenalis, is one of the most common treatable causes of gastroenteritis worldwide, with a burden higher in low-income countries."
    explanation: Supports globally common burden and low-income setting concentration.
epidemiology:
- name: Disproportionate burden by economic setting
  description: Disease burden is higher in low-income countries despite global distribution.
  factors:
  - low-resource sanitation and water infrastructure
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Giardiasis, caused by the protozoan parasite Giardia duodenalis, is one of the most common treatable causes of gastroenteritis worldwide, with a burden higher in low-income countries."
    explanation: Supports differential burden by setting.
- name: Risk profile in high-income countries
  description: Travel, untreated freshwater exposure, sexual contact, childcare contact, and recent antibiotics are key epidemiologic risk factors.
  factors:
  - international travel
  - untreated freshwater exposure
  - male-male sexual contact
  - contact with diapered children
  - recent antibiotic exposure
  - chronic gastrointestinal disease
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In high-income countries, risk factors for giardiasis include international travel, exposure to untreated freshwater sources, male-male sexual contact, contact with diapered children, recent antibiotic use, and underlying chronic gastrointestinal disease."
    explanation: Supports epidemiologic risk-factor stratification in high-income settings.
- name: European waterborne outbreak burden
  description: Recurrent outbreaks remain linked to recreational/drinking water contamination and treatment failures.
  factors:
  - recreational water
  - drinking water
  - treatment failures
  - heavy rainfall contamination events
  unit: outbreaks (2010-2024)
  evidence:
  - reference: PMID:41280732
    reference_title: "Giardia and Campylobacter: Fifteen years (2010-2024) of waterborne outbreaks in Europe."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Over 30 outbreaks were reported during the study period, primarily in Ireland and Nordic countries."
    explanation: Provides quantified outbreak burden for recent European surveillance.
  - reference: PMID:41280732
    reference_title: "Giardia and Campylobacter: Fifteen years (2010-2024) of waterborne outbreaks in Europe."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Recreational and drinking water sources were the most commonly implicated, with contamination events often associated with specific incidents or treatment failures, and heavy rainfall suggested as contributing factor to pathogen entry."
    explanation: Supports environmental drivers of recurrent outbreaks.
- name: Pediatric severity amplification in undernourished LMIC settings
  description: Children in low- and middle-income settings have higher symptom burden and long-term developmental risk when infected.
  factors:
  - undernutrition
  - immature immune system
  - host-parasite-microbiome interaction complexity
  evidence:
  - reference: PMID:37764167
    reference_title: "The Gut-Wrenching Effects of Cryptosporidiosis and Giardiasis in Children."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Children are more likely to have clinical symptoms due to their less developed immune systems and factors such as undernutrition, especially in low- and middle-income countries."
    explanation: Supports epidemiologic concentration of symptomatic burden in vulnerable pediatric populations.
  - reference: PMID:37764167
    reference_title: "The Gut-Wrenching Effects of Cryptosporidiosis and Giardiasis in Children."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Structural damages inflicted by both parasites to epithelial cells in the large and small intestines could severely impair children's gut health, including the ability to absorb nutrients, resulting in stunted growth, diminished neurocognitive development, and other long-term effects."
    explanation: Supports long-term developmental impact as part of pediatric disease burden.
progression:
- phase: Incubation and prepatent interval
  incubation_days: '8'
  notes: Median prepatent interval is 14 days and is usually under 3 weeks.
  evidence:
  - reference: PMID:68190
    reference_title: "Prepatency of giardiasis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The median incubation time of giardiasis was 8 days, and in two-thirds of the cases the symptoms had continued for over a week before the parasite became detectable in faeces."
    explanation: Supports median incubation timing and delayed stool detectability.
  - reference: PMID:68190
    reference_title: "Prepatency of giardiasis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The median prepatent period was 14 days, and in most cases the prepatent period was less than 3 wk."
    explanation: Supports prepatent timing in the early disease course.
- phase: Early diagnostic window with possible false-negative stool microscopy
  notes: Early post-exposure stool studies may be negative, requiring repeat sampling.
  evidence:
  - reference: PMID:68190
    reference_title: "Prepatency of giardiasis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A practical conclusion was that, in suspected cases of giardiasis with negative stool findings during the first 3 wk after possible exposure to Giardia, examination of repeated faecal samples is still effective in confirming the diagnosis."
    explanation: Supports repeated stool testing during early disease progression.
- phase: Chronic/persistent symptomatic infection
  notes: A subset progresses to prolonged malabsorptive disease with nutritional impact.
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In some patients, a chronic infection may lead to malabsorption and weight loss."
    explanation: Supports chronic progression beyond initial acute diarrhea.
- phase: Post-infectious gut-brain interaction sequelae
  notes: Long-term post-infectious IBS can persist years after acute gastroenteritis, with highest pooled prevalence in parasite-associated cohorts.
  evidence:
  - reference: DOI:10.1136/gutjnl-2023-331835
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PI-IBS was most associated with parasites (prevalence 30.1%), but in only two studies, followed by bacteria (18.3%) and viruses (10.7%)."
    explanation: Supports higher post-infectious IBS burden after parasitic gastroenteritis.
  - reference: DOI:10.1136/gutjnl-2023-331835
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "IBS persisted in 39.8% of subjects in the long-term (>5 years follow-up) after diagnosis."
    explanation: Supports long-term persistence of post-infectious sequelae.
pathophysiology:
- name: Ingestion of infectious Giardia cysts
  description: Infection begins with ingestion of environmentally transmitted cysts.
  downstream:
  - target: Trophozoite colonization of the proximal small-intestinal epithelial surface
    description: Ingested parasites establish non-invasive colonization at the mucosal surface.
    evidence:
    - reference: DOI:10.1128/iai.00065-24
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "G. lamblia resides in the lumen and at the epithelial surface of the proximal small intestine but is not mucosa invasive."
      explanation: Supports the transition from exposure to non-invasive luminal colonization.
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Giardiasis, caused by the protozoan parasite Giardia duodenalis, is one of the most common treatable causes of gastroenteritis worldwide, with a burden higher in low-income countries."
    explanation: Supports Giardia exposure as the initiating infectious event.
- name: Trophozoite colonization of the proximal small-intestinal epithelial surface
  description: Giardia trophozoites persist at the proximal small-intestinal lumen-epithelium interface without mucosal invasion.
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  downstream:
  - target: Assemblage-specific trophozoite-epithelial injury signaling
    description: Colonizing trophozoites initiate epithelial injury programs that vary by infecting assemblage.
    evidence:
    - reference: PMID:22924932
      reference_title: "Giardia duodenalis assemblage-specific induction of apoptosis and tight junction disruption in human intestinal epithelial cells: effects of mixed infections."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "The results indicate that infection with trophozoites disrupts epithelial tight junctions and induces varying degrees of enterocyte apoptosis, depending on the infecting assemblage."
      explanation: Supports assemblage-dependent epithelial injury signaling after trophozoite contact.
  evidence:
  - reference: DOI:10.1128/iai.00065-24
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "G. lamblia resides in the lumen and at the epithelial surface of the proximal small intestine but is not mucosa invasive."
    explanation: Supports non-invasive luminal colonization as a discrete mechanistic stage.
- name: Assemblage-specific trophozoite-epithelial injury signaling
  description: Host epithelial injury severity varies by Giardia assemblage and can intensify during mixed infections.
  downstream:
  - target: Caspase-3-dependent enterocyte apoptosis
    description: Trophozoite-triggered epithelial injury activates caspase-3-dependent apoptosis.
    evidence:
    - reference: PMID:22924932
      reference_title: "Giardia duodenalis assemblage-specific induction of apoptosis and tight junction disruption in human intestinal epithelial cells: effects of mixed infections."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "All disruptions were caspase-3 dependent and were more pronounced when caused by a non-host specific assemblage."
      explanation: Supports a caspase-3-dependent apoptotic injury step.
  - target: Tight-junction disassembly in infected enterocytes
    description: Trophozoite-triggered epithelial injury induces tight-junction disruption.
    evidence:
    - reference: PMID:22924932
      reference_title: "Giardia duodenalis assemblage-specific induction of apoptosis and tight junction disruption in human intestinal epithelial cells: effects of mixed infections."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "The results indicate that infection with trophozoites disrupts epithelial tight junctions and induces varying degrees of enterocyte apoptosis, depending on the infecting assemblage."
      explanation: Supports tight-junction disruption as a distinct epithelial injury event.
  evidence:
  - reference: PMID:22924932
    reference_title: "Giardia duodenalis assemblage-specific induction of apoptosis and tight junction disruption in human intestinal epithelial cells: effects of mixed infections."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Furthermore, infections by isolates in combination with isolates from another assemblage enhanced the epithelial disruption and apoptosis."
    explanation: Supports increased epithelial injury in mixed-assemblage infection contexts.
- name: Caspase-3-dependent enterocyte apoptosis
  description: Giardia-induced epithelial injury triggers caspase-3-dependent enterocyte apoptosis.
  cell_types:
  - preferred_term: enterocyte
    term:
      id: CL:0000584
      label: enterocyte
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
  downstream:
  - target: Epithelial barrier resistance decline
    description: Increased epithelial apoptosis contributes to loss of mucosal barrier integrity.
    evidence:
    - reference: PMID:16935925
      reference_title: "Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "As structural correlate, reduced claudin 1 expression and increased epithelial apoptosis were detected."
      explanation: Supports apoptosis as a contributor to barrier pathology in human duodenal tissue.
  evidence:
  - reference: PMID:22924932
    reference_title: "Giardia duodenalis assemblage-specific induction of apoptosis and tight junction disruption in human intestinal epithelial cells: effects of mixed infections."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "All disruptions were caspase-3 dependent and were more pronounced when caused by a non-host specific assemblage."
    explanation: Supports caspase-3 dependence of trophozoite-induced epithelial apoptosis.
- name: Tight-junction disassembly in infected enterocytes
  description: Giardia infection causes tight-junction disruption in intestinal epithelial cells.
  biological_processes:
  - preferred_term: tight junction disassembly
    term:
      id: GO:1905071
      label: tight junction disassembly
  downstream:
  - target: Claudin-1 downregulation
    description: Tight-junction injury is associated with reduced claudin-1 expression.
    evidence:
    - reference: PMID:16935925
      reference_title: "Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "As structural correlate, reduced claudin 1 expression and increased epithelial apoptosis were detected."
      explanation: Supports claudin-1 loss as a structural correlate of junctional injury.
  - target: Epithelial barrier resistance decline
    description: Tight-junction injury contributes to reduced epithelial resistance.
    evidence:
    - reference: PMID:16935925
      reference_title: "Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Instead, epithelial resistance of giardiasis biopsy specimens was decreased (19 (2) vs 25 (2) Omega cm(2); p<0.05)"
      explanation: Supports reduced epithelial resistance downstream of tight-junction injury.
  evidence:
  - reference: PMID:22924932
    reference_title: "Giardia duodenalis assemblage-specific induction of apoptosis and tight junction disruption in human intestinal epithelial cells: effects of mixed infections."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The results indicate that infection with trophozoites disrupts epithelial tight junctions and induces varying degrees of enterocyte apoptosis, depending on the infecting assemblage."
    explanation: Supports trophozoite-induced tight-junction disruption as a specific injury event.
- name: Claudin-1 downregulation
  description: Expression of the tight-junction protein claudin-1 is reduced in chronic human giardiasis.
  downstream:
  - target: Epithelial barrier resistance decline
    description: Claudin-1 loss contributes to impaired epithelial barrier function.
    evidence:
    - reference: PMID:16935925
      reference_title: "Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "CONCLUSIONS: G lamblia infection causes epithelial barrier dysfunction owing to down regulation of the tight junction protein claudin 1 and increased epithelial apoptoses."
      explanation: Supports causal linkage from claudin-1 downregulation to barrier dysfunction.
  evidence:
  - reference: PMID:16935925
    reference_title: "Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As structural correlate, reduced claudin 1 expression and increased epithelial apoptosis were detected."
    explanation: Supports reduced claudin-1 expression in human duodenal giardiasis.
- name: Hypoxia-dependent PKC alpha/beta II dephosphorylation
  description: Low-oxygen conditions in infected IECs drive PKC alpha/beta II dephosphorylation linked to barrier injury.
  biological_processes:
  - preferred_term: response to hypoxia
    term:
      id: GO:0001666
      label: response to hypoxia
  downstream:
  - target: Epithelial barrier resistance decline
    description: Hypoxia-dependent PKC signaling changes exacerbate permeability defects.
    evidence:
    - reference: PMID:35868574
      reference_title: "Oxygen-dependent regulation of permeability in low resistance intestinal epithelial cells infected with Giardia lamblia."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Using human cell lines HuTu-80 and Caco-2 as models of \"loose\" (low resistance) and \"tight\" (high resistance) intestines, respectively, we elucidated that low pO2 drives intestinal barrier dysfunction in IECs infected with trophozoites through dephosphorylation of protein kinase C (PKC α/β II)."
      explanation: Supports a specific low-pO2/PKC mechanism upstream of barrier dysfunction.
  evidence:
  - reference: PMID:35868574
    reference_title: "Oxygen-dependent regulation of permeability in low resistance intestinal epithelial cells infected with Giardia lamblia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Collectively, these results support the emerging theory that molecular oxygen impacts gut homeostasis during Giardia infection via direct host signaling pathways."
    explanation: Supports oxygen-regulated host-signaling perturbation in infected epithelial cells.
- name: Epithelial barrier resistance decline
  description: Human duodenal giardiasis is associated with reduced epithelial resistance and barrier dysfunction.
  downstream:
  - target: Sodium-glucose symport impairment
    description: Barrier pathology is accompanied by reduced Na-glucose absorption.
    evidence:
    - reference: PMID:16935925
      reference_title: "Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Finally, phlorizin-sensitive Na(+)-glucose symport was reduced in patients with giardiasis (121 (9) vs 83 (14) microA/h/cm(2))."
      explanation: Supports nutrient transport impairment downstream of epithelial barrier pathology.
  - target: Electrogenic anion secretion activation
    description: Barrier pathology is accompanied by increased secretory current.
    evidence:
    - reference: PMID:16935925
      reference_title: "Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The bumetanide-sensitive portion of I(SC) in giardiasis was also increased (51 (5) vs 20 (9) microA/h/cm(2) in control; p<0.05)."
      explanation: Supports increased anion-secretory component in chronic giardiasis.
  evidence:
  - reference: PMID:16935925
    reference_title: "Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Instead, epithelial resistance of giardiasis biopsy specimens was decreased (19 (2) vs 25 (2) Omega cm(2); p<0.05)"
    explanation: Supports reduced epithelial resistance as a discrete pathophysiologic event.
- name: Sodium-glucose symport impairment
  description: Sodium-dependent glucose transport is reduced in chronic human giardiasis.
  downstream:
  - target: Malabsorption
    description: Reduced sodium-glucose transport contributes to malabsorptive disease.
    evidence:
    - reference: PMID:16935925
      reference_title: "Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "CONCLUSIONS: G lamblia infection causes epithelial barrier dysfunction owing to down regulation of the tight junction protein claudin 1 and increased epithelial apoptoses. Na(+)-dependent d-glucose absorption is impaired and active electrogenic anion secretion is activated."
      explanation: Supports glucose-transport impairment as a mechanistic contributor to malabsorptive symptoms.
  evidence:
  - reference: PMID:16935925
    reference_title: "Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Finally, phlorizin-sensitive Na(+)-glucose symport was reduced in patients with giardiasis (121 (9) vs 83 (14) microA/h/cm(2))."
    explanation: Supports reduced sodium-glucose symport in chronic human infection.
- name: Electrogenic anion secretion activation
  description: Bumetanide-sensitive secretory current is increased in chronic human giardiasis.
  downstream:
  - target: Diarrhea
    description: Increased epithelial secretory drive contributes to diarrheal output.
    evidence:
    - reference: PMID:16935925
      reference_title: "Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "CONCLUSIONS: G lamblia infection causes epithelial barrier dysfunction owing to down regulation of the tight junction protein claudin 1 and increased epithelial apoptoses. Na(+)-dependent d-glucose absorption is impaired and active electrogenic anion secretion is activated."
      explanation: Supports secretory activation as a contributor to diarrheal pathogenesis.
  evidence:
  - reference: PMID:16935925
    reference_title: "Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The bumetanide-sensitive portion of I(SC) in giardiasis was also increased (51 (5) vs 20 (9) microA/h/cm(2) in control; p<0.05)."
    explanation: Supports activation of a bumetanide-sensitive anion-secretory component.
- name: Mucus layer disruption
  description: Giardia impairs mucus barrier integrity at the host-microbe interface.
  downstream:
  - target: Commensal microbiota biofilm impairment
    description: Mucus-layer perturbation is linked to altered commensal biofilm architecture.
    evidence:
    - reference: PMID:28452685
      reference_title: "Interactions of Giardia sp. with the intestinal barrier: Epithelium, mucus, and microbiota."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "We will summarize what is known and discuss preliminary observations suggesting how such enteropathogen directly and/ or indirectly impairs commensal microbiota biofilm architecture, disrupts mucus layer and damages host epithelium physiology and survival."
      explanation: Supports the causal relationship between mucus disruption and microbiota biofilm impairment.
  evidence:
  - reference: PMID:28452685
    reference_title: "Interactions of Giardia sp. with the intestinal barrier: Epithelium, mucus, and microbiota."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "We will summarize what is known and discuss preliminary observations suggesting how such enteropathogen directly and/ or indirectly impairs commensal microbiota biofilm architecture, disrupts mucus layer and damages host epithelium physiology and survival."
    explanation: Supports mucus disruption as a distinct barrier-level event.
- name: Commensal microbiota biofilm impairment
  description: Giardia-associated barrier perturbation disrupts commensal microbiota organization.
  downstream:
  - target: Malabsorption
    description: Microbiota and epithelial barrier perturbation may reinforce nutrient malabsorption.
    evidence:
    - reference: PMID:30020611
      reference_title: "Giardiasis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "In some patients, a chronic infection may lead to malabsorption and weight loss."
      explanation: Supports malabsorption as a downstream clinical consequence in persistent disease.
  evidence:
  - reference: PMID:28452685
    reference_title: "Interactions of Giardia sp. with the intestinal barrier: Epithelium, mucus, and microbiota."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "We will summarize what is known and discuss preliminary observations suggesting how such enteropathogen directly and/ or indirectly impairs commensal microbiota biofilm architecture, disrupts mucus layer and damages host epithelium physiology and survival."
    explanation: Supports commensal biofilm impairment as a discrete event in barrier ecosystem pathology.
- name: Malabsorption
  description: Chronic intestinal dysfunction in giardiasis can impair nutrient absorption.
  downstream:
  - target: Steatorrhea
    description: Fat malabsorption contributes to steatorrheal stool phenotype.
    evidence:
    - reference: PMID:6750750
      reference_title: "Giardiasis: nutritional implications."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Giardiasis can produce steatorrhea, maldigestion, and malabsorption of carbohydrates and of vitamins A and B12."
      explanation: Supports steatorrhea as a downstream manifestation of malabsorptive dysfunction.
  - target: Weight loss
    description: Prolonged malabsorption contributes to loss of body weight.
    evidence:
    - reference: PMID:30020611
      reference_title: "Giardiasis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "In some patients, a chronic infection may lead to malabsorption and weight loss."
      explanation: Supports direct linkage from malabsorption to weight loss.
  - target: Failure to thrive
    description: Severe pediatric nutritional compromise can present as failure to thrive.
    evidence:
    - reference: PMID:6750750
      reference_title: "Giardiasis: nutritional implications."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Severe clinical giardiasis can cause \"failure to thrive\" in young children, but the impact, if any, of subclinical giardiasis on growth in general populations is not well defined."
      explanation: Supports severe pediatric growth failure as a downstream clinical consequence in high-burden contexts.
  - target: Growth delay
    description: Chronic giardiasis in poorly nourished settings can contribute to linear growth faltering.
    evidence:
    - reference: PMID:14501998
      reference_title: "Giardia intestinalis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Further studies of giardiasis in poorly nourished children in developing regions supports an important contributing role of Giardia in stunting and cognitive impairment."
      explanation: Supports a downstream link between chronic giardiasis-associated nutritional disruption and growth delay.
  - target: Cognitive impairment
    description: In vulnerable pediatric populations, chronic giardiasis-associated nutritional disruption may contribute to cognitive deficits.
    evidence:
    - reference: PMID:14501998
      reference_title: "Giardia intestinalis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Further studies of giardiasis in poorly nourished children in developing regions supports an important contributing role of Giardia in stunting and cognitive impairment."
      explanation: Supports cognitive sequelae as a downstream consequence in undernourished pediatric settings.
  - target: Post-infectious irritable bowel syndrome
    description: A subset develops persistent post-infectious bowel dysfunction after acute gastroenteritis.
    evidence:
    - reference: DOI:10.1136/gutjnl-2023-331835
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Overall prevalence of PI-IBS and PI-FD were 14.5% and 12.7%, respectively."
      explanation: Supports clinically relevant long-tail post-infectious bowel sequelae.
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In some patients, a chronic infection may lead to malabsorption and weight loss."
    explanation: Supports malabsorption as a key downstream pathophysiologic outcome.
  - reference: PMID:35250996
    reference_title: "Mucosal Defense Against Giardia at the Intestinal Epithelial Cell Interface."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Chronic G. duodenalis infections cause a malabsorption syndrome that may lead to failure to thrive and/or stunted growth, especially in children in developing countries."
    explanation: Adds independent support linking chronic giardiasis to malabsorption syndrome and pediatric growth consequences.
phenotypes:
- name: Diarrhea
  category: Gastrointestinal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating; however, asymptomatic colonization is also common."
    explanation: Supports diarrhea as a hallmark frequent phenotype.
- name: Abdominal pain
  category: Gastrointestinal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating; however, asymptomatic colonization is also common."
    explanation: Supports abdominal pain as a common clinical manifestation.
  - reference: PMID:17070814
    reference_title: "Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Clinical manifestations of Giardia intestinalis infection also vary from asymptomatic carriage to acute and chronic diarrhoea with abdominal pain."
    explanation: Independent review support for abdominal pain across acute and chronic courses.
- name: Flatulence
  category: Gastrointestinal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Flatulence
    term:
      id: HP:0033589
      label: Flatulence
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating; however, asymptomatic colonization is also common."
    explanation: Supports flatulence as a common symptom.
- name: Abdominal distention
  category: Gastrointestinal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abdominal distention
    term:
      id: HP:0003270
      label: Abdominal distention
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The clinical presentation typically involves diarrhea, flatulence, abdominal pain, and bloating; however, asymptomatic colonization is also common."
    explanation: Supports abdominal bloating/distention as part of the common symptomatic presentation.
- name: Steatorrhea
  category: Gastrointestinal
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Steatorrhea
    term:
      id: HP:0002570
      label: Steatorrhea
  evidence:
  - reference: PMID:6750750
    reference_title: "Giardiasis: nutritional implications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Giardiasis can produce steatorrhea, maldigestion, and malabsorption of carbohydrates and of vitamins A and B12."
    explanation: Supports steatorrhea as a recognized malabsorptive manifestation.
- name: Malabsorption
  category: Gastrointestinal
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Malabsorption
    term:
      id: HP:0002024
      label: Malabsorption
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In some patients, a chronic infection may lead to malabsorption and weight loss."
    explanation: Supports malabsorption as an important chronic manifestation.
  - reference: PMID:35250996
    reference_title: "Mucosal Defense Against Giardia at the Intestinal Epithelial Cell Interface."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Chronic G. duodenalis infections cause a malabsorption syndrome that may lead to failure to thrive and/or stunted growth, especially in children in developing countries."
    explanation: Provides independent support for chronic malabsorption as a clinically important manifestation.
- name: Weight loss
  category: Constitutional
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In some patients, a chronic infection may lead to malabsorption and weight loss."
    explanation: Supports weight loss in persistent/chronic disease.
- name: Failure to thrive
  category: Pediatric growth and nutrition
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:6750750
    reference_title: "Giardiasis: nutritional implications."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Severe clinical giardiasis can cause \"failure to thrive\" in young children, but the impact, if any, of subclinical giardiasis on growth in general populations is not well defined."
    explanation: Supports failure to thrive as a severe pediatric nutritional consequence.
  - reference: PMID:35250996
    reference_title: "Mucosal Defense Against Giardia at the Intestinal Epithelial Cell Interface."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Chronic G. duodenalis infections cause a malabsorption syndrome that may lead to failure to thrive and/or stunted growth, especially in children in developing countries."
    explanation: Adds newer independent support for failure-to-thrive risk in chronic pediatric infection.
- name: Growth delay
  category: Pediatric growth and nutrition
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Growth delay
    term:
      id: HP:0001510
      label: Growth delay
  evidence:
  - reference: PMID:14501998
    reference_title: "Giardia intestinalis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Further studies of giardiasis in poorly nourished children in developing regions supports an important contributing role of Giardia in stunting and cognitive impairment."
    explanation: Supports growth delay/stunting as a documented pediatric consequence in vulnerable settings.
  - reference: PMID:37764167
    reference_title: "The Gut-Wrenching Effects of Cryptosporidiosis and Giardiasis in Children."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Structural damages inflicted by both parasites to epithelial cells in the large and small intestines could severely impair children's gut health, including the ability to absorb nutrients, resulting in stunted growth, diminished neurocognitive development, and other long-term effects."
    explanation: Adds contemporary review support linking intestinal injury and malabsorption to pediatric stunting.
- name: Cognitive impairment
  category: Neurodevelopmental sequelae
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:14501998
    reference_title: "Giardia intestinalis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Further studies of giardiasis in poorly nourished children in developing regions supports an important contributing role of Giardia in stunting and cognitive impairment."
    explanation: Supports potential neurodevelopmental sequelae (cognitive impairment) in pediatric chronic exposure contexts.
  - reference: PMID:37764167
    reference_title: "The Gut-Wrenching Effects of Cryptosporidiosis and Giardiasis in Children."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Structural damages inflicted by both parasites to epithelial cells in the large and small intestines could severely impair children's gut health, including the ability to absorb nutrients, resulting in stunted growth, diminished neurocognitive development, and other long-term effects."
    explanation: Adds independent contemporary support for long-term neurocognitive impact in pediatric disease contexts.
- name: Post-infectious irritable bowel syndrome
  category: Post-infectious sequelae
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: irritable bowel syndrome
    term:
      id: MONDO:0005052
      label: irritable bowel syndrome
  evidence:
  - reference: DOI:10.1136/gutjnl-2023-331835
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PI-IBS was most associated with parasites (prevalence 30.1%), but in only two studies, followed by bacteria (18.3%) and viruses (10.7%)."
    explanation: Supports parasite-linked post-infectious IBS as a relevant sequela category.
  - reference: DOI:10.1136/gutjnl-2023-331835
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "IBS persisted in 39.8% of subjects in the long-term (>5 years follow-up) after diagnosis."
    explanation: Supports long-term persistence of this sequela once established.
- name: Post-infectious dyspepsia
  category: Post-infectious sequelae
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Dyspepsia
    term:
      id: HP:0410281
      label: Dyspepsia
  evidence:
  - reference: DOI:10.1136/gutjnl-2023-331835
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Overall prevalence of PI-IBS and PI-FD were 14.5% and 12.7%, respectively."
    explanation: Supports post-infectious dyspeptic symptoms (PI-FD) as a recognized long-tail sequela after enteric infection.
histopathology: []
biochemical: []
genetic: []
environmental:
- name: Untreated freshwater exposure
  description: Exposure to untreated freshwater increases acquisition risk.
  effect: Increases risk of waterborne giardiasis.
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In high-income countries, risk factors for giardiasis include international travel, exposure to untreated freshwater sources, male-male sexual contact, contact with diapered children, recent antibiotic use, and underlying chronic gastrointestinal disease."
    explanation: Supports untreated freshwater as an environmental risk factor.
- name: Childcare and close-contact fecal-oral exposure
  description: Contact with diapered children and close household/sexual contact contexts increase transmission risk.
  effect: Increases person-to-person transmission probability.
  evidence:
  - reference: PMID:30020611
    reference_title: "Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In high-income countries, risk factors for giardiasis include international travel, exposure to untreated freshwater sources, male-male sexual contact, contact with diapered children, recent antibiotic use, and underlying chronic gastrointestinal disease."
    explanation: Supports close-contact transmission-promoting environments.
- name: Water infrastructure failure and rainfall-associated contamination
  description: Outbreaks are associated with treatment failures and rainfall-driven contamination events.
  effect: Increases risk of community waterborne outbreaks.
  evidence:
  - reference: PMID:41280732
    reference_title: "Giardia and Campylobacter: Fifteen years (2010-2024) of waterborne outbreaks in Europe."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Recreational and drinking water sources were the most commonly implicated, with contamination events often associated with specific incidents or treatment failures, and heavy rainfall suggested as contributing factor to pathogen entry."
    explanation: Supports infrastructure and weather-linked environmental amplification of risk.
treatments:
- name: Nitroimidazole pharmacotherapy (tinidazole or metronidazole)
  description: Nitroimidazoles are core first-line agents for most uncomplicated giardiasis.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: tinidazole
      term:
        id: CHEBI:63627
        label: tinidazole
    - preferred_term: metronidazole
      term:
        id: CHEBI:6909
        label: metronidazole
  evidence:
  - reference: PMID:15625030
    reference_title: "Treatment of Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Tinidazole is the first-line drug treatment of giardiasis, as it requires only a single dose to cure infection in most individuals."
    explanation: Supports tinidazole as first-line therapy.
  - reference: PMID:15625030
    reference_title: "Treatment of Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The related drug metronidazole is as effective, but it requires 5 to 7 days of three times a day therapy."
    explanation: Supports metronidazole as an effective alternative regimen.
- name: Nitazoxanide alternative therapy
  description: Nitazoxanide is an alternative antiprotozoal with efficacy comparable to nitroimidazoles in selected studies.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:15625030
    reference_title: "Treatment of Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Nitazoxanide appears in limited studies to be as effective as tinidazole or metronidazole, and it does not have the bitter taste of nitroimidazoles."
    explanation: Supports nitazoxanide as a reasonable alternative option.
  - reference: PMID:18348774
    reference_title: "The treatment of giardiasis in children: single-dose tinidazole compared with 3 days of nitazoxanide."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among the 137 children who completed the study (74 given nitazoxanide and 63 given tinidazole), the frequency of parasitological cure following a single dose of tinidazole was significantly higher than that following six doses of nitazoxanide (90.5% v. 78.4%; P<0.05)."
    explanation: Randomized pediatric trial provides comparative efficacy context for nitazoxanide versus tinidazole.
- name: Paromomycin in pregnancy or nitroimidazole-constrained settings
  description: Paromomycin is a non-absorbed alternative used when systemic nitroimidazoles are less desirable.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: paromomycin
      term:
        id: CHEBI:7934
        label: paromomycin
  evidence:
  - reference: PMID:15625030
    reference_title: "Treatment of Giardiasis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A good alternate for use during pregnancy is paromomycin."
    explanation: Supports paromomycin as a pregnancy-compatible alternative.
- name: Investigational therapy for resistant/refractory giardiasis
  description: Repurposed agents are under study for resistant or recurrent disease phenotypes.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: DOI:10.1128/aac.00731-23
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Fexinidazole and its metabolites were also active against a metronidazole-resistant strain of G. lamblia."
    explanation: Supports active development of alternatives for resistant cases.
  - reference: clinicaltrials:NCT02736968
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study is designed to compare placebo to once daily doses of 6mg auranofin for adults with amebiasis or giardiasis."
    explanation: Supports active human trial evaluation of repurposed therapy in giardiasis.
diagnosis:
- name: Repeated stool microscopy strategy in early suspected infection
  description: Initial negative stool microscopy does not exclude early giardiasis and repeat sampling improves diagnostic yield.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
    qualifiers:
    - predicate:
        preferred_term: diagnostic procedure
        term:
          id: NCIT:C18020
          label: Diagnostic Procedure
      value:
        preferred_term: microscopy
        term:
          id: NCIT:C16853
          label: Microscopy
  evidence:
  - reference: PMID:68190
    reference_title: "Prepatency of giardiasis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A practical conclusion was that, in suspected cases of giardiasis with negative stool findings during the first 3 wk after possible exposure to Giardia, examination of repeated faecal samples is still effective in confirming the diagnosis."
    explanation: Supports repeat stool examination strategy in early disease.
- name: Stool antigen enzyme immunoassay
  description: Stool antigen immunoassay provides high sensitivity/specificity and detects cases missed by conventional O&P microscopy.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
    qualifiers:
    - predicate:
        preferred_term: diagnostic procedure
        term:
          id: NCIT:C18020
          label: Diagnostic Procedure
      value:
        preferred_term: ELISA
        term:
          id: NCIT:C16553
          label: ELISA
  evidence:
  - reference: PMID:2674196
    reference_title: "Stool diagnosis of giardiasis using a commercially available enzyme immunoassay to detect Giardia-specific antigen 65 (GSA 65)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "When these six specimens were accepted as true-positives, the immunoassay detected almost 30% more cases of Giardia infection than did O&P examination."
    explanation: Supports higher case detection by antigen immunoassay.
  - reference: PMID:2674196
    reference_title: "Stool diagnosis of giardiasis using a commercially available enzyme immunoassay to detect Giardia-specific antigen 65 (GSA 65)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Its sensitivity and specificity were 96 and 100%, respectively, while the sensitivity and specificity of O&P examination were 74 and 100%, respectively."
    explanation: Provides comparative diagnostic performance metrics.
- name: ELISA versus microscopy evaluation in pediatric stool diagnosis
  description: Pediatric diagnostic protocols continue to compare immunoassay and microscopy approaches.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
    qualifiers:
    - predicate:
        preferred_term: diagnostic procedure
        term:
          id: NCIT:C18020
          label: Diagnostic Procedure
      value:
        preferred_term: ELISA
        term:
          id: NCIT:C16553
          label: ELISA
    - predicate:
        preferred_term: diagnostic procedure
        term:
          id: NCIT:C18020
          label: Diagnostic Procedure
      value:
        preferred_term: microscopy
        term:
          id: NCIT:C16853
          label: Microscopy
  evidence:
  - reference: clinicaltrials:NCT06533696
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The present study was done to evaluate the efficacy of Human anti Giardia lamblia antibody (ELISA) kitst in comparison to direct microscopy in the diagnosis of G. lamblia in stool specimens from immunocompetent and immunocompromised children with diarrhea and other gastrointestinal symptoms."
    explanation: Supports direct trial-level comparison of immunoassay and microscopy diagnostic workflows.
differential_diagnoses:
- name: Amebiasis
  description: Amebic colitis can mimic chronic or recurrent giardiasis-associated bowel symptoms.
  disease_term:
    preferred_term: amebiasis
    term:
      id: MONDO:0005644
      label: amebiasis
  distinguishing_features:
  - Amebiasis may present as non-dysenteric amoebic colitis that overlaps symptomatically with IBS-like syndromes.
  - Species-specific stool testing helps discriminate Entamoeba from Giardia.
  evidence:
  - reference: PMID:17070814
    reference_title: "Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Although Entamoeba histolytica infections occur predominately in developing regions of the world, clinical diagnosis of amebiasis is often difficult because symptoms of patients with IBS may closely mimic those patients with non-dysenteric amoebic colitis."
    explanation: Supports amebiasis as a clinically relevant mimic requiring differential diagnosis.
- name: Cryptosporidiosis
  description: Another protozoan diarrheal infection with overlapping watery diarrhea phenotypes and waterborne exposure context.
  disease_term:
    preferred_term: cryptosporidiosis
    term:
      id: MONDO:0015474
      label: cryptosporidiosis
  distinguishing_features:
  - Shared waterborne epidemiology may require pathogen-specific stool testing for discrimination.
  - Persistent protozoal diarrhea in immunocompromised hosts should include both Giardia and Cryptosporidium testing.
  evidence:
  - reference: PMID:41280732
    reference_title: "Giardia and Campylobacter: Fifteen years (2010-2024) of waterborne outbreaks in Europe."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "Giardia and Campylobacter are two key waterborne pathogens and leading agents of gastrointestinal illnesses."
    explanation: Supports waterborne protozoal differential context; species-level stool diagnostics remain necessary.
- name: Irritable bowel syndrome
  description: Functional bowel disorders can be misclassified when persistent protozoal infection is not excluded.
  disease_term:
    preferred_term: irritable bowel syndrome
    term:
      id: MONDO:0005052
      label: irritable bowel syndrome
  distinguishing_features:
  - Giardia can produce recurrent IBS-like symptoms that persist for years.
  - Routine parasitological stool workup helps avoid mislabeling protozoal infection as functional IBS.
  evidence:
  - reference: PMID:17070814
    reference_title: "Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These IBS-like symptoms can be continuous, intermittent, sporadic or recurrent, sometimes lasting years without correct diagnosis."
    explanation: Supports diagnostic overlap between chronic giardiasis and IBS.
  - reference: PMID:17070814
    reference_title: "Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It is essential that all patients with IBS undergo routine parasitological investigations in order to rule out the presence of protozoan parasites as the causative agents of the clinical signs."
    explanation: Supports explicit parasitology testing to distinguish giardiasis from IBS.
clinical_trials:
- name: NCT02736968
  phase: PHASE_II
  status: UNKNOWN
  description: Phase IIa randomized placebo-controlled trial of oral auranofin in adults with giardiasis or amebiasis.
  target_phenotypes:
  - preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  evidence:
  - reference: clinicaltrials:NCT02736968
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is a phase IIa, randomized, placebo-controlled, single-blinded superiority treatment study in males and non-pregnant females, 18 to 65 years of age who are in good health."
    explanation: Supports interventional adult trial framework for giardiasis treatment evaluation.
  - reference: clinicaltrials:NCT02736968
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study is designed to compare placebo to once daily doses of 6mg auranofin for adults with amebiasis or giardiasis."
    explanation: Supports direct drug-versus-placebo efficacy evaluation in giardiasis.
- name: NCT06533696
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: Pediatric study comparing stool microscopy and ELISA for Giardia diagnosis in symptomatic children.
  target_phenotypes:
  - preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  evidence:
  - reference: clinicaltrials:NCT06533696
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The present study was done to evaluate the efficacy of Human anti Giardia lamblia antibody (ELISA) kitst in comparison to direct microscopy in the diagnosis of G. lamblia in stool specimens from immunocompetent and immunocompromised children with diarrhea and other gastrointestinal symptoms."
    explanation: Supports an active diagnostic-method comparison study in pediatric giardiasis.
datasets:
- accession: geo:GSE36490
  title: Analysis of the transcriptomes of Giardia intestinalis assemblages A, B, and E using strand-specific RNA-seq
  description: >-
    Strand-specific bulk RNA-seq resource profiling trophozoites from multiple
    Giardia intestinalis assemblages linked to host preference and symptom
    heterogeneity in giardiasis.
  organism:
    preferred_term: Giardia duodenalis
    term:
      id: NCBITaxon:5741
      label: Giardia duodenalis
  data_type: BULK_RNA_SEQ
  conditions:
  - assemblage A (WB, AS175)
  - assemblage B (GS)
  - assemblage E (P15)
  publication: PMID:23555231
  evidence:
  - reference: GEO:GSE36490
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We have performed strand-specific RNA-seq of trophozoites from four different Giardia intestinalis strains (A=WB and AS175, B=GS, E=P15)."
    explanation: GEO summary directly supports accession content and parasite-stage context.
  - reference: PMID:23555231
    reference_title: "Transcriptome profiling of Giardia intestinalis using strand-specific RNA-seq."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Four genetically different isolates were studied (WB (AI), AS175 (AII), P15 (E) and GS (B)) using paired-end, strand-specific RNA-seq."
    explanation: PMID abstract corroborates multi-assemblage transcriptomic design relevant to Giardia pathogenesis biology.
  notes: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36490
- accession: geo:GSE158187
  title: Steady-state expression of Giardia lamblia transcripts
  description: >-
    Giardia trophozoite RNA-seq dataset used to quantify steady-state transcript
    expression and support refined Giardia gene models relevant to parasite
    biology in giardiasis.
  organism:
    preferred_term: Giardia duodenalis
    term:
      id: NCBITaxon:5741
      label: Giardia duodenalis
  data_type: BULK_RNA_SEQ
  conditions:
  - steady-state trophozoite transcript expression
  publication: PMID:35110372
  evidence:
  - reference: GEO:GSE158187
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "RNASequencing and RNA level measurements of G. lamblia transcripts during trophozite stage to compare expression between genes of interest"
    explanation: GEO summary supports the transcriptomic scope and trophozoite stage.
  - reference: PMID:35110372
    reference_title: "Precise gene models using long-read sequencing reveal a unique poly(A) signal in Giardia lamblia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Using long-read sequencing, we characterize the polyadenylation signal and related sequences surrounding Giardia lamblia cleavage sites for over 2600 genes."
    explanation: Abstract supports transcript-level molecular characterization aligned with this dataset.
  notes: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158187
- accession: geo:GSE168675
  title: Defining Giardia lamblia cleavage sites
  description: >-
    Long-read and 3' end sequencing dataset defining mRNA cleavage sites and
    polyadenylation features in Giardia trophozoites, supporting post-transcriptional
    mechanism studies relevant to giardiasis.
  organism:
    preferred_term: Giardia duodenalis
    term:
      id: NCBITaxon:5741
      label: Giardia duodenalis
  data_type: BULK_RNA_SEQ
  conditions:
  - 3-prime end and long-read sequencing for cleavage-site mapping
  publication: PMID:35110372
  evidence:
  - reference: GEO:GSE168675
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "3'-end sequencing and Oxford Nanopore Technologies long-read sequencing of trophozoite RNA to define mRNA cleavage sites"
    explanation: GEO summary directly supports the dataset's sequencing strategy and biological material.
  - reference: PMID:35110372
    reference_title: "Precise gene models using long-read sequencing reveal a unique poly(A) signal in Giardia lamblia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We find that G. lamblia uses an AGURAA poly(A) signal, which differs from the mammalian AAUAAA."
    explanation: PMID abstract supports disease-relevant molecular findings from cleavage/polyadenylation analyses.
  notes: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE168675
references:
- reference: DOI:10.1007/s40475-024-00314-2
  title: Current Understanding of Giardia lamblia and Pathogenesis of Stunting and Cognitive Deficits in Children from Low- and Middle-Income Countries
  found_in:
  - Giardiasis-deep-research-falcon.md
  findings:
  - statement: Current Understanding of Giardia lamblia and Pathogenesis of Stunting and Cognitive Deficits in Children from Low- and Middle-Income Countries
    supporting_text: Current Understanding of Giardia lamblia and Pathogenesis of Stunting and Cognitive Deficits in Children from Low- and Middle-Income Countries
- reference: DOI:10.1186/s13099-024-00666-0
  title: Occurrence and assemblage distribution of Giardia Duodenalis in symptomatic and asymptomatic patients in southeastern Iran (2019–2022)
  found_in:
  - Giardiasis-deep-research-falcon.md
  findings:
  - statement: Occurrence and assemblage distribution of Giardia Duodenalis in symptomatic and asymptomatic patients in southeastern Iran (2019–2022)
    supporting_text: Occurrence and assemblage distribution of Giardia Duodenalis in symptomatic and asymptomatic patients in southeastern Iran (2019–2022)
- reference: DOI:10.1371/journal.pntd.0012230
  title: Giardia lamblia risk factors and burden in children with acute gastroenteritis in a Nicaraguan birth cohort
  found_in:
  - Giardiasis-deep-research-falcon.md
  findings:
  - statement: Giardia lamblia is an intestinal protozoan estimated to cause ~200 million symptomatic infections annually, mainly in children in low- and middle-income countries associated with intestinal damage, increased permeability, and malabsorption.
    supporting_text: Giardia lamblia is an intestinal protozoan estimated to cause ~200 million symptomatic infections annually, mainly in children in low- and middle-income countries associated with intestinal damage, increased permeability, and malabsorption.
    evidence:
    - reference: DOI:10.1371/journal.pntd.0012230
      reference_title: Giardia lamblia risk factors and burden in children with acute gastroenteritis in a Nicaraguan birth cohort
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Giardia lamblia is an intestinal protozoan estimated to cause ~200 million symptomatic infections annually, mainly in children in low- and middle-income countries associated with intestinal damage, increased permeability, and malabsorption.
      explanation: Deep research cited this publication as relevant literature for Giardiasis.
- reference: DOI:10.20944/preprints202403.1207.v1
  title: 'Protozoan Infections Acquired from Food or Drinking Water: An Update'
  found_in:
  - Giardiasis-deep-research-falcon.md
  findings:
  - statement: 'Protozoan Infections Acquired from Food or Drinking Water: An Update'
    supporting_text: This review summarizes the most recent developments of research on protozoan parasite infections ac-quired through food and drinking water and is aimed at gathering updated knowledge on the risk factors, illnesses caused, and measures for prevention.
    evidence:
    - reference: DOI:10.20944/preprints202403.1207.v1
      reference_title: 'Protozoan Infections Acquired from Food or Drinking Water: An Update'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: This review summarizes the most recent developments of research on protozoan parasite infections ac-quired through food and drinking water and is aimed at gathering updated knowledge on the risk factors, illnesses caused, and measures for prevention.
      explanation: Deep research cited this publication as relevant literature for Giardiasis.
- reference: DOI:10.2166/wh.2024.107
  title: 'Waterborne <i>Cryptosporidium</i> species and <i>Giardia duodenalis</i> in resources of MENA: A systematic review and meta-analysis'
  found_in:
  - Giardiasis-deep-research-falcon.md
  findings:
  - statement: This review explores our understanding of Cryptosporidium species and Giardia duodenalis distribution in Middle East and North African (MENA) water resources.
    supporting_text: This review explores our understanding of Cryptosporidium species and Giardia duodenalis distribution in Middle East and North African (MENA) water resources.
    evidence:
    - reference: DOI:10.2166/wh.2024.107
      reference_title: 'Waterborne <i>Cryptosporidium</i> species and <i>Giardia duodenalis</i> in resources of MENA: A systematic review and meta-analysis'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: This review explores our understanding of Cryptosporidium species and Giardia duodenalis distribution in Middle East and North African (MENA) water resources.
      explanation: Deep research cited this publication as relevant literature for Giardiasis.
- reference: DOI:10.2807/1560-7917.es.2024.29.20.2300509
  title: 'Autochthonous and imported giardiasis cases: An analysis of two decades of national surveillance data, Germany, 2002 to 2021'
  found_in:
  - Giardiasis-deep-research-falcon.md
  findings:
  - statement: Giardia duodenalis is a major cause of gastroenteritis globally, and is the most common food- and waterborne parasitic infection in Europe.
    supporting_text: Giardia duodenalis is a major cause of gastroenteritis globally, and is the most common food- and waterborne parasitic infection in Europe.
    evidence:
    - reference: DOI:10.2807/1560-7917.es.2024.29.20.2300509
      reference_title: 'Autochthonous and imported giardiasis cases: An analysis of two decades of national surveillance data, Germany, 2002 to 2021'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Giardia duodenalis is a major cause of gastroenteritis globally, and is the most common food- and waterborne parasitic infection in Europe.
      explanation: Deep research cited this publication as relevant literature for Giardiasis.
- reference: DOI:10.3390/diagnostics14040364
  title: 'Systematic Review of Diagnostic Approaches for Human Giardiasis: Unveiling Optimal Strategies'
  found_in:
  - Giardiasis-deep-research-falcon.md
  findings:
  - statement: Giardiasis, caused by the protozoan Giardia intestinalis, affects around 400 million people worldwide, emphasizing the critical need for accurate diagnosis to enhance human health, especially in children.
    supporting_text: Giardiasis, caused by the protozoan Giardia intestinalis, affects around 400 million people worldwide, emphasizing the critical need for accurate diagnosis to enhance human health, especially in children.
    evidence:
    - reference: DOI:10.3390/diagnostics14040364
      reference_title: 'Systematic Review of Diagnostic Approaches for Human Giardiasis: Unveiling Optimal Strategies'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Giardiasis, caused by the protozoan Giardia intestinalis, affects around 400 million people worldwide, emphasizing the critical need for accurate diagnosis to enhance human health, especially in children.
      explanation: Deep research cited this publication as relevant literature for Giardiasis.
- reference: DOI:10.3390/ijms25168627
  title: The Influence of the Protozoan Giardia lamblia on the Modulation of the Immune System and Alterations in Host Glucose and Lipid Metabolism
  found_in:
  - Giardiasis-deep-research-falcon.md
  findings:
  - statement: Giardia lamblia, the cause of giardiasis, significantly impacts patients with metabolic disorders related to insulin resistance (IR).
    supporting_text: Giardia lamblia, the cause of giardiasis, significantly impacts patients with metabolic disorders related to insulin resistance (IR).
    evidence:
    - reference: DOI:10.3390/ijms25168627
      reference_title: The Influence of the Protozoan Giardia lamblia on the Modulation of the Immune System and Alterations in Host Glucose and Lipid Metabolism
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Giardia lamblia, the cause of giardiasis, significantly impacts patients with metabolic disorders related to insulin resistance (IR).
      explanation: Deep research cited this publication as relevant literature for Giardiasis.
- reference: DOI:10.51891/rease.v10i10.15915
  title: 'GIARDÍASE: DIAGNÓSTICO, TRATAMENTO E ABORDAGENS MULTIDISCIPLINARES'
  found_in:
  - Giardiasis-deep-research-falcon.md
  findings:
  - statement: A giardíase é uma infecção intestinal causada pelo protozoário Giardia lamblia, frequentemente associada a quadros de diarreia, dor abdominal e desidratação.
    supporting_text: A giardíase é uma infecção intestinal causada pelo protozoário Giardia lamblia, frequentemente associada a quadros de diarreia, dor abdominal e desidratação.
    evidence:
    - reference: DOI:10.51891/rease.v10i10.15915
      reference_title: 'GIARDÍASE: DIAGNÓSTICO, TRATAMENTO E ABORDAGENS MULTIDISCIPLINARES'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: A giardíase é uma infecção intestinal causada pelo protozoário Giardia lamblia, frequentemente associada a quadros de diarreia, dor abdominal e desidratação.
      explanation: Deep research cited this publication as relevant literature for Giardiasis.
- reference: DOI:10.5772/intechopen.1005559
  title: Perspectives on the Drug Discovery of Intestinal Protozoan Parasites
  found_in:
  - Giardiasis-deep-research-falcon.md
  findings:
  - statement: The intestinal protozoan parasites pose serious health concerns, infecting more than one billion individuals every year and mainly causing diarrhea in infants and adults.
    supporting_text: The intestinal protozoan parasites pose serious health concerns, infecting more than one billion individuals every year and mainly causing diarrhea in infants and adults.
    evidence:
    - reference: DOI:10.5772/intechopen.1005559
      reference_title: Perspectives on the Drug Discovery of Intestinal Protozoan Parasites
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The intestinal protozoan parasites pose serious health concerns, infecting more than one billion individuals every year and mainly causing diarrhea in infants and adults.
      explanation: Deep research cited this publication as relevant literature for Giardiasis.